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ABSTRACT 
Background: Prostate cancer (PCa) is one of the leading causes of cancer mortality and 
incidence in Canada. Saskatchewan has one of highest mortality and incidence rates in Canada, 
and this doctoral research explores possible reasons for the higher mortality and incidence rates 
in Saskatchewan compared to the other provinces. While reasons for these PCa outcomes are not 
known, we hypothesize healthcare access factors may influence PCa outcomes, including PCa 
incidence, treatment usage and time trends in Saskatchewan, and we hypothesize additional 
factors may affect PCa treatment decision-making. To explore these hypotheses, in this 
dissertation we study the following research questions: (1) “Is the PCa incidence in 
Saskatchewan affected by changes in family physician density, the remoteness level of where a 
patient lives, and the closest PCa assessment centre from where a patient lives?”; (2) “Are the 
PCa treatment utilization rates in Saskatchewan affected by changes in the remoteness level of 
where a patient lives and the closest PCa assessment centre from where a patient lives?”; (3)  
“Are the PCa time-to-treatment outcomes in Saskatchewan affected by changes in the 
remoteness level of where a patient lives and the closest PCa assessment centre from where a 
patient lives?”; and (4) “What factors and corresponding themes in the literature have been 
identified to affect the treatment decision-making of localized prostate cancer patients in Canada 
and the United States?”. 
Methods: To explore research questions one, two, and three, we used data from: (1) 
Saskatchewan Cancer Registry, (2) Statistics Canada’s Index of Remoteness, (3) Canadian 
Medical Association, and (4) Saskatchewan Covered Population. To explore research question 
four, we used data from: (1) MEDLINE, (2) EMBASE, (3) CINAHL, (4) AMED and (5) 
PsycInfo. For our first research question, we estimated the standardized incidence ratios (SIRs) 
of PCa and their associations with family physician density, remoteness level of where a patient 
lives and closest PCa assessment centre from where a patient lives in Saskatchewan using the 
Besag, York and Mollie (BYM) Bayesian method. For our second research question, we built 
multilevel generalized linear models to estimate the relationship between treatment choice and 
factors including remoteness level of where a patient lives and closest PCa assessment centre 
from where a patient lives. For our third research question, we conducted multivariable analysis 
to assess whether remoteness level of where a patient lives and closest PCa assessment centre 
from where a patient lives are associated with PCa time-to-treatment outcomes. For our fourth 
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research question, we conducted a scoping review using the process of Arksey and O’Malley to 
identify key factors commonly studied in localized PCa treatment decision-making. 
Results: Family physician density was negatively associated with SIRs of metastatic PCa (IRR = 
0.935; 95% CrI: 0.880 to 0.998]) and SIR of high-risk PCa (IRR = 0.927 ; 95% CrI: 0.880 to 
0.975). We found that patients living in the rural areas have lower odds (OR = 0.59; 95% CI: 
0.45	to	0.77; P < .001) of having surgery compared to patients living in the greater urban areas. 
RT diagnosis-to-treatment time was positively correlated with the remoteness-index (IRR = 1.45; 
95% CI: 1.21 to 1.75; P < .001). Five themes in localized PCa treatment decision-making were 
identified: treatment type, socioeconomic characteristics, personal reasons, psychological 
experience, and involvement in the decision-making process. 
Conclusions: Healthcare access factors were associated with PCa incidence, treatment choice 
and treatment delays in Saskatchewan. We found family physician density was negatively 
associated with incidence of high risk and metastatic PCa. There were regional disparities in PCa 
treatment choice and residents living in rural/remote areas were associated with delays for PCa 
treatment. We found five key factors associated with PCa treatment decision-making. This work 
informs future research and cancer care practices and policies to improve PCa patient outcomes 
in Saskatchewan and Canada. 
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CHAPTER 1 – INTRODUCTION 
Prostate cancer (PCa) is the leading cause of cancer among Canadian men, accounting for 
1 in 5 new cancer cases in Canada (1). In 2020, PCa was estimated to cause of third highest 
number of deaths from cancer among Canadian men (after lung and colorectal) (1).  Based on the 
latest 2019 Canadian provincial estimates, Saskatchewan had the highest projected age-
standardized mortality rate (29.8 deaths per 100,000) and third highest projected age-
standardized incidence rate (117.8 cases per 100,000), compared to other provinces (2). This 
doctoral research explores possible reasons for the lower survival and higher mortality rates in 
Saskatchewan, when compared to other provinces. 
To explore possible reasons for the Saskatchewan rates, first we need background 
information regarding diagnosis, classification, and treatment procedures for PCa. The first 
section in this chapter describes diagnosing PCa. The second section describes the classification 
of PCa that could influence treatments received by patients. The third section describes the 
treatments for PCa. The fourth section looks at how healthcare access in Saskatchewan affects 
diagnosis and treatment outcomes for PCa. The last sections in the chapter respectively provide 
the problem statement and study objectives/research questions for this doctoral research, and the 
references used throughout the chapter. 
1.1. Diagnosis of PCa 
The first step of PCa diagnosis involves two common methods of PCa screening:  a 
digital rectal exam (DRE) and a prostate-specific antigen (PSA) test (3).  The DRE screening 
method involves a physical examination where the size and consistency of the prostate gland are 
examined (3). The DRE focuses on identifying abnormalities (including indications of hard, 
nodular and irregular areas) during the examination of the prostate gland and the surrounding 
area (3). While about 1 in 4 abnormal DREs may be due to PCa, an abnormal DRE could be 
indicative of other cancers or prostate conditions (3). The second screening method is via a blood 
test identifying the concentration of a specific molecule produced by the prostate gland: the 
prostate-specific antigen (PSA) (4), because PCa can lead to elevated levels of PSA in the blood 
(5). The efficacy of using a PSA test to screen for PCa is compromised because several other 
conditions affecting the prostate gland (such as chronic prostatitis and benign prostatic 
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hypertrophy), can lead to elevated PSA levels in the blood (4). Consequently, screening for PCa 
via PSA testing (i.e., PSA screening) is a controversial topic. The poor sensitivity and specificity 
of PSA tests in detecting PCa and the overall harm-to-benefit ratio associated with early 
detection of PCa have led to mixed recommendations for PSA screening (5).  
The Canadian Task Force on Preventive Health Care (CTFPHC) recommends against 
using PSA tests for PCa screening in all men (6). The United States Preventative Service Task 
Force (USPSTF) recommends PCa screening via PSA tests based on patient’s preference among 
men who are 55 to 69 years old (7). The USPSTF also recommends that PCa screening via PSA 
tests should be based on family history, race/ethnicity, comorbid conditions, other identified 
health risks and patient preferences (7). The differing recommendations provided by the 
CTFPHC and USPSTF on PCa screening via PSA tests add to the challenge for healthcare 
providers on how to best approach PCa detection and diagnosis (8). 
In spite of the challenges associated with using a DRE and a PSA test to diagnosis PCa, 
the diagnosis of PCa is initiated based on an abnormal DRE during physical examination and/or 
raised PSA levels (typically more than 4.0 ng/mL) in the blood sample (9). The confirmation of a 
PCa diagnosis is based on a prostate biopsy (9).  
Studying PCa diagnosis patterns in a population assists in identifying if the cancer was 
detected early in prognosis or if there were any patterns of late detection.  Diagnosis patterns for 
PCa could be assessed using incidence rate, which measures the number of newly diagnosed 
cases in each area or population over a specified period of time (10). Due to the high PCa 
incidence rate in Saskatchewan (as mentioned earlier), this thesis assesses PCa diagnosis patterns 
in Chapter 3 (2). Specifically, in Chapter 3 we study PCa diagnosis patterns in Saskatchewan, 
stratified by different classifications of PCa (with further details on classification of PCa being 
provided in the next section). 
1.2. Classification of PCa 
In men diagnosed with PCa, the biopsy is used to classify the PCa using clinical staging, 
anatomic staging, and risk levels. The clinical staging of PCa is based on the TNM (T=tumor, 
N=node, M=metastasis) staging system (9). The T, N and M stages respectively measure the 
size/extent of the tumor, spread of the tumor to any lymph nodes and spread of the tumor to 
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distant parts of the body (11). In the process of assigning an anatomic stage, a grading system 
called Gleason score is used, which involves assigning a score to the cancerous cells based on 
their appearance and behavior (9). 
The TNM stage, Gleason score, and PSA levels are used to categorize the PCa into 
anatomic stages (using the American Joint Committee on Cancer staging, 7th Edition) (12). The 
anatomic stages include Stages I, IIA, IIB, III and IV (12). The TNM staging is also used to 
categorize PCa as localized, locally extensive and metastasized (9). PCa in patients with T1 or 
T2 T-stage with no spread to the lymph nodes or distant parts of the body is considered localized 
(9). PCa in patients with T3 or T4 T-stage with no spread of the tumor to the lymph nodes or 
distant parts of the body is considered locally extensive (9). PCa in patients at any T-stage where 
the tumor has spread to the lymph nodes or distant parts of the body is considered metastasized 
(9).  
Table 1.1. Genitourinary Radiation Oncologists of Canada (GUROC) criteria for risk categories 
(13). 
Risk Category PSA Value Gleason Score Clinical T Stage 
Low (must have all) ≤10 ng/mL ≤6 T1-T2a 
Intermediate (must have all else low risk) ≤20 ng/mL 7 T1/T2 
High (any one is sufficient) >20 ng/mL 8-10 T3a-T4 
 
PCa cases are also classified into risk levels. The risk levels are regarding PCa 
biochemical recurrence, where recurrence or relapse of PCa means the cancer has returned after 
it has been treated (14). After treatment if the only sign of recurrence is PSA elevation, then it is 
called biochemical recurrence (14). While a PSA ≥ 0.2 ng/dL is the commonly used definition, 
currently there is no consensus on a standard definition measuring biochemical recurrence 
among post-treatment PCa patients (15). The risk levels for PCa biochemical recurrence among 
non-metastasized PCa patients can be derived pre-treatment using the TNM stage, Gleason score 
and PSA levels (16, 17). These risk levels are assigned as low, intermediate or high and were 
developed by D’Amico et al. in 1998 (17). Since then, several modifications of these risk levels 
have been proposed and adopted by different organizations including the Genito-Urinary 
Radiation Oncologists of Canada (GUROC) (Table 1.1) (18). Since both D’Amico and GUROC 
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risk classifications are widely used as a tool by physicians for assisting patients in choosing 
appropriate treatments for PCa, in Chapter 3, 4, 5 and 6 we further considered D’Amico/GUROC 
risk classification when studying PCa outcomes. In this doctoral research, the term “outcomes” 
refers to PCa standardized incidence ratios in Chapter 3, PCa treatment choices in Chapter 4, 
PCa time-to-treatment results in Chapter 5 and PCa treatment decision-making themes in 
Chapter 6. 
1.3. Treatments for PCa 
The appropriate treatment for PCa depends on several factors including the risk level, 
TNM stage, Gleason score, treatment side effects, age, life expectancy, comorbidity and patient 
preferences (19). There are four general treatment options for localized (see section 1.2 for 
definition) PCa: active surveillance/watchful waiting, prostatectomy or surgery, radiation 
therapy, and hormonal therapy (19). For locally extensive and metastasized PCa, the treatment 
options could be a combination of surgery, radiation therapy, hormonal therapy and 
chemotherapy (19). In Canada, the most commonly used PCa treatments vary between provinces 
(13). For surgery, beside provincial variations in the usage, rates of use also depend on the PCa 
risk level (with the highest rates among intermediate-risk) and the age of the patient (with the 
lowest rates among patients over the age of 75) (13). Among high-risk PCa patients, radiation 
therapy is the most common treatment (13). In Canada, PCa treatment statistics for active 
surveillance/watchful waiting and hormonal therapy (similar to what is described for surgery and 
radiation therapy earlier) are not available (13). These commonly used treatments described 
above are available in Saskatchewan, including active surveillance/watchful waiting, surgery, 
radiation therapy and hormonal therapy (20). In Saskatchewan, surgery and radiation therapy for 
PCa are available in two cities – Saskatoon and Regina  (21, 22). Hence, the residents living 
outside of Saskatoon and Regina travel to receive their surgery or radiation therapy treatment. In 
Chapter 4 of this thesis, we study PCa treatment patterns in Saskatchewan. 
Treatment patterns for PCa could be influenced by treatment decision-making factors 
including patient preferences (19). A recent report in Canada emphasized the need for 
prioritizing individual needs in the treatment decision making process (13). Treatment decision 
making can be facilitated using decision aids and other educational tools for patients (13). 
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Decision to choose a treatment may be influenced by the types of treatment side effects 
associated with a given treatment (23-29). Patients prefer a shared treatment decision making 
process with their healthcare provider (30). In this thesis, we further explore PCa decision 
making factors in Chapter 6. 
Receiving timely treatment is also necessary to improve PCa patient outcomes (31-34). In 
Canada, wait times for PCa related surgeries are known to be longer than for surgeries for other 
major cancer types (breast, lung, colorectal and bladder) (35). In addition, wait times for surgery 
and radiation therapy vary between provinces (13). For patients, both the choice of, and timing 
for, PCa treatment can be influenced by the availability of, and access to, PCa treatments (36, 
37). Availability and access are two of the five components that define healthcare access. 
Research shows how both of these components can influence one’s PCa treatment choice (36-
38). Since healthcare access factors may influence treatment outcomes, in Chapter 4 and 5 of this 
thesis, we explore treatment outcomes in Saskatchewan and their association (if any) with 
healthcare access factors. Further details on healthcare access are provided in the next section. 
1.4. Healthcare Access 
Healthcare access is defined as the fit between the patient and the health care system, that 
can be measured based on the following components: availability, accessibility, accommodation, 
affordability and acceptability (38). Availability refers to the adequacy of the resources (e.g., 
number of physicians, facilities, etc.) to meet the patient demands; accessibility refers to the role 
of geography (e.g., distance, travel, time) when a patient is seeking healthcare; accommodation 
refers to the structure (e.g., hours of operation, wait-time) of the healthcare system that addresses 
patients and their needs appropriately; affordability is the role of finance (e.g., insurance, 
income, ability to pay) when a patient is seeking healthcare; and acceptability is the role of 
attitude (e.g., patient or provider’s age, sex, ethnicity, cultural responsiveness) when a patient is 
seeking healthcare (38).  
In the literature, the components of healthcare access are associated with various PCa 
outcomes (39-42). For example, in terms of the availability component of healthcare access, 
research from the United States shows that there is an association between the number of 
urologists in a geographic area and PCa mortality rates (a negative correlation) (39). In terms of 
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accessibility, one study found factors, including higher incomes and living in rural areas, 
influence how much people are willing to travel for PCa radiation treatment to larger and more 
established treatment locations (40). In terms of accommodation, a recent report shows nearly a 
third of PCa patients in Saskatchewan had to wait for their first consultation appointment without 
receiving any explanation for the delay, leading to frustration and anxiety (13). In terms of 
affordability, a study in the United States found uninsured PCa patients face treatment delays 
(41), which have been associated with adverse pathological outcomes (42). In Canada, PCa 
patients have reported lack of support in paying extra costs associated related to cancer care (13). 
In terms of acceptability, a Canadian report has emphasized the importance of patient-centred 
approaches in PCa care through communication, information sharing and shared-decision 
making with patients (13). The acceptability component includes cultural factors that may 
influence patient decision-making in seeking care (43). Culturally appropriate care is key to 
improving acceptability in the health system through addressing bias, discrimination and racism; 
expanding patient-centred approaches; and meeting the holistic care needs of patients (44). In 
Canada, the acceptability of the health services impacts the health outcomes of Indigenous 
peoples (44).  
Returning our focus to Saskatchewan, healthcare access is known to be an issue in 
Saskatchewan (45, 46). Studies have found issues regarding healthcare provider availability, 
longer driving distances (accessibility), and concerns regarding wait-times (accommodation) (45, 
46).  There is no literature regarding whether healthcare access is affecting incidence and 
treatment rates among Saskatchewan PCa patients. 
1.5. Research Gaps, Objectives and Questions 
To our knowledge, no literature discusses the reasons for the high incidence and mortality 
rates in Saskatchewan, compared to other provinces. Specifically, there are no studies assessing 
associations (if any) between healthcare access factors in Saskatchewan and PCa incidence, 
treatment utilization and treatment delays. While the current literature on treatment decision-
making studies focuses on factors for specific patient profiles, for example, ethnic and racial 
minorities, different age groups, and specific treatment options (23, 24, 26, 27, 47-50), we did 
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not find any literature that comprehensively identifies overarching themes regarding factors 
affecting localized PCa treatment decision-making.  
Based on the research gaps identified in the previous sections, the objectives of this study 
are to:  
1. determine the associations (if any) between components of healthcare access and 
each of PCa incidence, treatment usage and time-to-treatment trends among 
Saskatchewan patients; and  
2. identify and describe the overarching themes influencing treatment decision-
making for localized PCa patients. 
To address Objective 1, we propose the following research questions: (1) “Is the PCa 
incidence in Saskatchewan affected by changes in family physician density, the remoteness level 
of where a patient lives, and the closest PCa assessment centre from where a patient lives?”; (2) 
“Are the PCa treatment utilization rates in Saskatchewan affected by changes in the remoteness 
level of where a patient lives and the closest PCa assessment centre from where a patient lives?”; 
and (3)  “Are the PCa time-to-treatment outcomes in Saskatchewan affected by changes in the 
remoteness level of where a patient lives and the closest PCa assessment centre from where a 
patient lives?”. To address Objective 2, we propose the research question: “What factors and 
corresponding themes in the literature have been identified to affect the treatment decision-
making of localized prostate cancer patients in Canada and the United States?”.  
In this dissertation, we explore these four research questions. Chapter 2 (Methods) 
describes the data sources, data, and the study design used to study each research question. 
Chapter 3 explores Research Question 1 of Objective 1, where we identify clusters of higher and 
lower than expected PCa incidence in Saskatchewan, assess the effects that different healthcare 
access factors have on the estimated PCa incidence in Saskatchewan, and identify any 
geographical disparities in risk-stratified PCa incidence in Saskatchewan. Chapter 4 explores 
Research Question 2 of Objective 1, where we identify the possible relationship between one’s 
initially-chosen PCa treatment and different healthcare access factors, and we identify any 
regional disparities in PCa treatment utilization. Chapter 5 explores Research Question 3 of 
Objective 1, where we assess the associations between time-to-treatment outcomes and different 
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healthcare access factors, and we identify possible regional disparities in PCa time-to-treatment 
outcomes. Chapter 6 explores Research Question 1 of Objective 2, where we systematically 
identify several factors affecting PCa treatment-decision-making in Canada and the United 
States. Chapter 7 concludes the doctoral research and identifies future areas of research 
exploration. 
The University of Saskatchewan BioMedical Research Ethics Board provided ethics 
approval (Bio-REB certificate #15-34) for this doctoral research (Appendix A). 
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CHAPTER 2 – METHODS 
This chapter provides the data sources, data descriptions, and study design used to 
explore the two objectives for this research:  
Objective 1: determine the associations (if any) between components of healthcare access and 
each of PCa incidence, treatment usage and time-to-treatment trends among 
Saskatchewan patients; and 
Objective 2: identify and describe the overarching themes influencing treatment decision-making 
for localized PCa patients.  
2.1. Data Sources 
In this section, we first summarize the needed data sources and the data variables 
extracted from the data sources to address Objectives 1 and 2.  
2.1.1. Data Sources to Study Objective 1 
There were four data sources used to study Objective 1: (1) Saskatchewan Cancer 
Registry, (2) Statistics Canada’s Index of Remoteness, (3) Canadian Medical Association’s 
physician density, and (4) Government of Saskatchewan’s Covered Population (1-4). This 
section describes each of these data sources and the data extracted from these sources. 
2.1.1.1. The Saskatchewan Cancer Registry (SCR) 
The Saskatchewan Cancer Registry (SCR) is a database of cancer health information for 
cancer patients diagnosed in Saskatchewan and is administered by the Saskatchewan Cancer 
Agency (1). The SCR consists of patient data on demographics, medical history, diagnostic 
findings, cancer information, cancer therapy, follow-up and death information (1). The SCR data 
obtained for this study consisted of information for 3,526 PCa patients diagnosed in 
Saskatchewan between 2010 and 2014. The SCR data consisted of following information on PCa 
patients: five-year age groups of patients (starting from age group of “35-39” till oldest age 
group of 90+; note age was not available as a continuous variable), diagnosis date (date PCa was 
diagnosed in the patient per the SCR), treatment types and dates (start date of treatments 
including chemotherapy, hormonal therapy, radiation therapy and surgery; ready to treat date for 
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radiation therapy), clinical staging information (PSA value, Gleason score, TNM-stage), and 
geographic locations of the patients. The SCR does not collect the treatment status of patients 
when their treatments were active surveillance/watchful waiting. Consequently, we assumed that 
patients in the SCR with no treatment status information were undergoing active 
surveillance/watchful waiting. For the geographic locations of the patients, the SCR categorized 
Saskatchewan communities in central and southern Saskatchewan into 82 geographic areas 
(GAs) using residence codes for privacy reasons (Figure 2.1) (4). Northern Saskatchewan could 
not be subdivided into smaller geographic areas due to privacy reasons. In addition, there were 
not enough data from northern Saskatchewan to allow statistical modelling (i.e., cell counts were 
less than 5 for the variables of interest). Hence, northern Saskatchewan was not included in any 
analyses. 
2.1.1.2. Statistic Canada’s Index of Remoteness 
To quantify the remoteness of a geographical area, we derived the remoteness index for a 
GA using the Index of Remoteness developed by Statistics Canada for Canadian communities, 
because the Index of Remoteness accounts for the size of the population and proximity to all 
population centres (2). The values for Statistics Canada’s Index of Remoteness range from 0 to 1 
with higher values equating to higher remoteness levels (2).  
2.1.1.3. Canadian Medical Association 
Physician count data for the province of Saskatchewan were sourced from the Canadian 
Medical Association for the year 2011, because the 2011 data were the only available data for 
the time period between 2010 and 2014 (3). The retrieved data consisted of a count of family 
physicians and general practitioners licensed to practice medicine within Saskatchewan, and 
Canadian Medical Association provided the data using Statistics Canada’s Census Subdivision 
geographic boundaries (5). The Canadian Medical Association sourced its information from The 
College of Family Physicians of Canada (CFPC), The Royal College of Physicians and Surgeons 
of Canada, individual Canadian Medical Association members and Collège des médecins du 
Québec (CMQ) (6-8). When determining physician counts, the Canadian Medical Association 
excluded retired physicians, physicians older than 80 (who were assumed retired), medical 
residents, medical students and anyone without a current valid mailing address. 
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2.1.1.4. Saskatchewan Covered Population 
To generate standardized incidence ratios (SIRs) (mentioned in section 2.1.1.1), 
Saskatchewan Covered Population (SCP) data were used. The SCP is a count of eligible 
individuals with health insurance benefit in Saskatchewan (4). The SCP consists of all residents 
in Saskatchewan with exception of: (a) member of Canadian Forces, (b) inmates of federal 
prison, and (c) those who do not meet residency requirements for Saskatchewan (4). Because the 
overall SCP data deviated less than 3% each year between 2010 and 2014 (9), we chose to use 
the data from the midpoint year 2012 (between 2010 and 2014) to generate SIRs (10). Further 
details about SIRs are available in Chapter 3. 
 
Figure 2.1: Defined geographic areas and major cities in the study sample in 
Saskatchewan. 
 
2.1.2. Data Sources to Study Objective 2 
There were five data sources to study Objective 2: (1) MEDLINE, (2) EMBASE, (3) 
CINAHL, (4) AMED and (5) PsycInfo. Data were compiled from each of the data sources using 
the inclusion and exclusion criteria described in Chapter 6. 
2.1.2.1. MEDLINE 
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MEDLINE is a bibliographic database that contains references and journal articles in the 
life sciences (11).  
2.1.2.2 EMBASE  
Similar to MEDLINE, EMBASE is a bibliographic database that contains references and 
journal articles in the life sciences (12).  
2.1.2.3. CINAHL 
CINAHL is a bibliographic database that contains references and journal articles for 
nursing and allied professional, and includes topics on biomedicine and consumer health (13).  
2.1.2.4. AMED  
Allied and Complementary Medicine Database (AMED) is a bibliographic database that 
is designed for healthcare providers and focuses on alternative and allied therapies (14).  
2.1.2.5. PsycInfo  
PsycInfo is a bibliographic database that contains references and journal articles in 
behavioural and social science (15).  
2.2. Research Question 1 of Objective 1 
Our first research question to study Objective 1 was “Is the PCa incidence in 
Saskatchewan affected by changes in family physician density, the remoteness level of where a 
patient lives, and the closest PCa assessment centre from where a patient lives?”. In this section, 
we first summarize the data used from the data sources and then the methodologies used to 
generate information to explore this question. Details for the complete study can be found in 
Chapter 3. 
2.2.1. Data and Variables 
For this study, data from four sources were used: (1) Saskatchewan Cancer Registry 
(SCR), (2) Statistics Canada’s Remoteness of Index, (3) Canadian Medical Association, and (4) 
Saskatchewan Covered Population (all described in section 2.1.1). We used the SCP (section 
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2.1.1.4) data and PCa case counts per GA from the SCR to derive four outcome variables based 
on the GUROC risk levels: (1) low risk SIRs, (2) intermediate risk SIRs, (3) high risk SIRs and 
(4) metastatic SIRs. To compute a SIR for a GA for a specific outcome variable, the numerator 
was the number of associated PCa patients (i.e., patients with a particular GUROC level) in the 
GA and the denominator was the value from the Saskatchewan Covered Population data (section 
2.1.1.4.) (full details can be found in Chapter 3). 
The independent variables used in this study were closest PCa assessment centre to a GA, 
GA remoteness index, and physician density for a GA. For privacy reasons, the exact residence 
locations of the patients were not available, hence the data needed to calculate a patient’s driving 
distances to different PCa assessment centres were not available. Consequently, we used the 
centroids of the GAs as the approximate location of where patients live within a GA and where 
treatment centres were located within a GA. Then the closest PCa assessment centre (as Regina 
or Saskatoon) to each GA was calculated based on the shortest Euclidean distance between the 
centroid of the GA and the centroids of Saskatoon and Regina. We derived the GA remoteness 
index as the average of the Statistics Canada Indices of Remoteness for the regions forming the 
GA (Figure 2.1) (2). To compute the physician density of a GA, we derived the numerator: 
physician count for a geographic area, to be the sum of the physician counts for the Census 
Subdivision areas forming the GA, and the denominator using Saskatchewan Covered Population 
data (section 2.1.1.4.) (details of the specific calculation can be found in Chapter 3).  
2.2.2. Study Design 
We used an ecological study design to address our research question, that is to assess if 
there were any associations between healthcare access factors (including closest PCa assessment 
centre to a GA, physician density and GA remoteness index) and PCa SIRs in Saskatchewan 
(16). For this study, we used SIRs to account for the varying population sizes of the GAs, and to 
identify areas with lower or higher than expected incidences of PCa for each risk levels. Given 
the nature of geographic data, the presence of spatial dependence in the PCa SIRs would violate 
the assumption of independence between the SIRs in a statistical analysis (17). To determine 
this, Global Moran’s I statistics were used to identify the existence of any spatial dependence in 
the PCa SIRs (18). We also used exploratory spatial statistics, including the Local Moran’s I and 
the Spatial Scan Statistics to identify clusters of higher than and lower than expected SIRs in 
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Saskatchewan (18-20). The Bayesian spatial analysis method introduced by Besag, York, and 
Mollie (BYM model) was used to account for any spatial dependence when assessing the 
associations (if any) between healthcare access factors and PCa SIRs (details for each of the 
statistical methods can be found in Chapter 3) (16, 21). The spatial smoothing of the PCa SIRs 
using the BYM method reduced the “noise” (i.e., large fluctuations) in the data while taking into 
account information from neighbouring GAs. Hence, the spatial smoothing of the PCa SIRs 
enhanced the process of identifying underlying patterns of PCa incidence in Saskatchewan (22). 
An advantage of using an ecological study design is that it allows studying an area-level 
measurement (PCa incidence in a geographic area) that cannot be measured at an individual level 
(17). This methodology also allows the assessment of area-level exposures (healthcare access 
factors), including physician density, GA remoteness index and the closest PCa assessment 
centre to a GA. An advantage of using spatial analysis when assessing the association between 
PCa incidence and the healthcare access factors is that the estimated errors and statistical 
significance were adjusted for any spatial dependence (if it exists) (23). A strength of using 
Bayesian spatial methods is that it allows for estimating reliable disease rates in low population 
areas (given the low-density population of Saskatchewan) because of the flexibility of Bayesian 
models to account for uncertainties or biases due to possible spatial and non-spatial variations in 
the disease (22, 24-26). Hence, spatial analysis improved the estimated measures assessing 
association between PCa incidence and healthcare access factors. 
2.3. Research Question 2 of Objective 1 
Our second research question related to study Objective 1 was “Are the PCa treatment 
utilization rates in Saskatchewan affected by changes in the remoteness level of where a patient 
lives and the closest PCa assessment centre from where a patient lives?”. Here we summarize the 
needed data, and then describe the methodologies used to generate information needed to explore 
this question. Details for the complete study can be found in Chapter 4. 
2.3.1. Data and Variables 
For this study, data from two data sources were used: (1) Saskatchewan Cancer Registry 
(SCR), and (2) Statistics Canada’s Remoteness of Index (both described in section 2.1.1). Our 
outcome variables were based on a patient choosing a particular PCa treatment within 2-years of 
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PCa diagnosis, which was based on the Canadian Partnership Against Cancer definition (27). 
Treatment dates for each type of PCa treatment and PCa diagnosis dates were used to derive four 
outcome variables: surgery (yes/no), radiation therapy (yes/no), hormonal therapy (yes/no), and 
chemotherapy (yes/no) as follows. If a PCa patient had surgery within 2 years after PCa 
diagnosis, our surgery variable was assigned “Yes”; otherwise, it was assigned “No”.  The same 
process was used to derive our radiation therapy, hormonal therapy, and chemotherapy variables. 
A fifth outcome variable (active surveillance/watchful waiting) was derived with the value “Yes” 
if a patient did not undergo radiation therapy, hormonal therapy, surgery and chemotherapy 
within 2 years after PCa diagnosis, or “No” otherwise.  
We used closest PCa assessment centre to a GA (section 2.2.1.) and GA remoteness 
index (section 2.2.1.) as the independent variables of interest. From Statistics Canada’s 
Remoteness of Index data, we also derived an urban/rural categorical variable for each GA. The 
criteria for assigning urban/rural categories were based on the GA remoteness index ranges for 
census metropolitan areas and smaller areas (2). The GA remoteness index values less than 0.35 
were categorized as “greater urban area” because, per Statistics Canada’s remoteness index, all 
large cities in Canada (known as Census Metropolitan Areas) were in that range (2). The GA 
remoteness index values greater than 0.40 were categorized as “rural” because no city were in 
that range (2).   
This study also accounted for other variables including age groups (<60, 60-69, 70-79, 80 
or above) and year of diagnosis (2010, 2011, 2012, 2013, 2014) derived from the SCR data 
source using the age at diagnosis and date of diagnosis variables (section 2.1.1.), respectively. 
The study also accounted GUROC risk level derived (as described in Section 2.2.1.). For the 
study, we used all but the chemotherapy outcome variable (due to lack of data).  Because patient 
level information on physician access was not available and we used patient level information for 
this study, we did not include physician access as one of the study variables. Further details 
regarding the study variables are provided in Chapter 4. 
2.3.2. Study Design 
Chapter 4 used a cross-sectional study design to assess if there was any association 
between the type of PCa treatment and the healthcare access factors: the geographic area in 
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which a patient lives and the GA remoteness index. A multilevel hierarchical modelling 
approach was used to fit hierarchical linearized regression models accounting for individual and 
community-level information to the data (17). Hence we fit hierarchical multilevel models to 
incorporate and investigate the effect of the geographical areas where patients live (a contextual 
community-level effect) associated with PCa treatment choices in Saskatchewan, while assessing 
the impact of demographic differences among patients: age, year of diagnosis, and GUROC risk 
level (individual-level effects) (details for each of the statistical methods can be found in Chapter 
4). 
The reason for fitting hierarchical multilevel models was due to the possible clustered-
data structure that could result from patients living in the same geographic area possibly having 
correlated observations, which can violate the assumption of independence when conducting 
linearized regression analysis (17), and hierarchical multilevel modelling can account for any 
correlation or clustering within the data structure (17). Hence, the use of hierarchical multilevel 
modelling adjusted the standard errors and statistical significance when assessing the association 
between PCa treatment utilization and healthcare access factors (17). 
2.4. Research Question 3 of Objective 1 
Our third research question to study Objective 1 was “Are the PCa time-to-treatment 
outcomes in Saskatchewan affected by changes in the remoteness level of where a patient lives 
and the closest PCa assessment centre from where a patient lives?”. Similar to previous sections, 
we first summarize the needed data and then describe the methodologies used to generate the 
information needed to explore this question. Details for the complete study can be found in 
Chapter 5. 
2.4.1. Data and Variables 
To address Research Question 3 of Objective 1, the outcome variables for this study 
were: (1) time from the PCa diagnosis date to the radiation therapy treatment date; and (2) time 
from the PCa “ready-to-treat” date to the radiation therapy treatment date. Both outcomes were 
derived using SCR data source using the PCa diagnosis date, radiation therapy “ready-to-treat” 
date, and radiation treatment date (section 2.1.1.). Only radiation therapy time-to-treatment 
outcomes were assessed because time-to-treatment data for other PCa treatments were not 
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available. The first outcome (time from PCa diagnosis to radiation therapy) was calculated as the 
difference between PCa diagnosis date and radiation therapy start date. The second outcome 
variable (time from PCa “ready to treat” to radiation therapy) was calculated as the difference 
between the PCa “ready to treat” date and the radiation therapy start date. 
The variables of interest for the study were closest PCa assessment centre to a GA and 
GA remoteness index as derived in section 2.2.1. From Statistics Canada’s Remoteness of Index 
data source, the chapter used the GA remoteness index variable to assess if any differences exist 
in PCa time-to-treatment outcomes among patients living in remote regions compared to urban 
areas. This study also accounted for other variables including age groups (<60, 60-69, 70-79, 80 
or above), year of diagnosis (2010, 2011, 2012, 2013, 2014), GUROC risk level and number of 
treatments as derived in sections 2.1.1 and 2.2.1. 
 Similar to Chapter 4, since this chapter used patient level information, and patient level 
information on physician access was not available, this chapter was not able to assess physician 
access. Further details are available in Chapter 5. 
2.4.2. Study Design 
Chapter 5 used a cross-sectional design using secondary cancer registry data to assess if 
there were any associations between healthcare access factors (including geographic location 
where patient lives and GA remoteness index) and PCa time-to-treatment outcomes. First, this 
study assessed the associations between healthcare access factors and PCa time-to-treatment 
outcomes using non-parametric statistics (including Mann Whitney U two sample statistic and 
Kruskal-Wallis equality-of-population rank test). Median time-to-treatment estimates for PCa 
were readily available in the literature, and to provide comparable estimates to the literature, a 
median-based analysis was conducted (a median based analysis assesses the ranking of 
observations including the median to test differences between samples, unlike a parametric 
analysis which assesses the mean and variance of the samples) (28). In addition, due to the count 
nature of the outcomes, count regression modelling was used, controlling for age, year of 
diagnosis and GUROC risk level in the analysis (17). The count regression analysis included 
Poisson and zero-inflated negative binomial analyses (details for each of the statistical methods 
can be found in Chapter 5).  
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Multivariable regression analysis accounted for several factors or potential confounders 
(age, year of diagnosis, GUROC risk level) when assessing the association between time-to-
treatment outcomes and healthcare access factors (17). Similar to Chapter 4, clustering within the 
data structure was also assessed. The zero-inflated negative binomial model accounted for the 
excess zero counts and over-dispersion in the time-to-treatment outcomes (17). Hence, the use of 
count regression models improved the estimation of any associations between PCa time-to-
treatment outcomes and healthcare access factors. 
2.5. Research Question 1 of Objective 2 
Our research question to study Objective 2 was “What factors and corresponding themes 
in the literature have been identified to affect the treatment decision-making of localized prostate 
cancer patients in Canada and the United States?”. In this section, we first summarize the data 
sources used to identify relevant literature, data collection process and then the methodologies 
used to generate information to explore this question. Details for the complete study can be 
found in Chapter 6. 
2.5.1. Data Collection Process 
This chapter collected and assessed the relevant literature using the scoping review 
method developed by Arksey and O’Malley (29). A list of search terms was used in the five data 
sources (details of search terms and search strategy are available in Chapter 6). Two reviewers 
were involved and data collection steps involved removal of duplicate literature material, and 
applying the inclusion and exclusion criteria (listed in Chapter 6). Both reviewers independently 
applied the inclusion/exclusion criteria in the review process. From each selected relevant article, 
general topics were extracted and documented. Further details available in Chapter 6. 
2.5.2. Study Design 
 We conducted a scoping review, as described by Arksey and O’Malley, to identify 
factors and corresponding themes that affect the treatment decision-making of localized PCa 
patients in Canada and the United States (29). The themes within the relevant literature were 
identified using principal component analysis (30-32). In addition, a Word Cloud consisting of 
information from the title and abstracts of the relevant literature was generated to assess 
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complementary results to the principal component analysis. The use of a scoping review, 
principal component analysis, and a word cloud provided a systematic process for identifying 
overarching themes in the literature regarding factors affecting PCa treatment decision-making. 
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CHAPTER 3 – GEOGRAPHIC DISPARITIES IN PROSTATE CANCER AND ITS 
ASSOCIATION WITH PHYSICIAN DENSITY IN SASKATCHEWAN: ANALYSIS USING 
BAYESIAN MODELS 
Article reproduced with permission and minor edits. Originally published as: Andkhoie 
M, Szafron M. Geographic disparities in prostate cancer and its association with physician 
density in Saskatchewan: analysis using Bayesian models. BMC Cancer. 2021. 21(1): 948; 
https://dx.doi.org/10.1186/s12885-021-08646-2. My contributions to this study include data 
acquisition, study design, data analysis, interpretation of findings and manuscript preparation. 
In this chapter, we present the complete study used to address the research question “Is 
the PCa incidence in Saskatchewan affected by changes in family physician density, the 
remoteness level of where a patient lives, and the closest PCa assessment centre from where a 
patient lives?” associated with our first study objective “to determine the associations (if any) 
between components of healthcare access and each of PCa incidence, treatment usage and time-
to-treatment trends among Saskatchewan patients”. Specifically, in this chapter, we identify 
clusters of higher and lower than expected prostate cancer (PCa) incidence in Saskatchewan. 
Further, we assess the effects of family physician density on the estimated PCa incidence in 
Saskatchewan. We identify clusters of PCa stratified by risk levels using Global Moran’s I, Local 
Moran’s I and Kuldorff’s Spatial Scan Statistics. We then estimate the standardized incidence 
ratios (SIRs) of PCa and their association with family physician density in Saskatchewan using 
the Besag, York and Mollie (BYM) Bayesian method. Clustering analysis identified higher than 
expected clusters of crude SIR for metastatic PCa in north-east Saskatchewan and lower than 
expected clusters in south-east Saskatchewan. Areas in north-west Saskatchewan have lower 
than expected crude SIR for both intermediate-risk and low-risk PCa. Family physician density 
was negatively associated with SIR of metastatic PCa (IRR: 0.935 [CrI: 0.880 to 0.998]) and SIR 
of high-risk PCa (IRR: 0.927 [CrI: 0.880 to 0.975]). We identify the geographical disparities in 
risk-stratified PCa incidence in Saskatchewan. Finally, we show that areas with lower densities 
of family physicians have higher than expected incidences of metastatic and high-risk PCa. 
Hence policies to increase physician supply should ensure an equitable geographic distribution of 
primary care physicians to support early detection of diseases, including PCa. 
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3.1. Introduction 
Prostate cancer (PCa) accounts for about 20% of all new cancer cases among men in 
Canada (1). Within Canada, the incidence rate of PCa varies between provinces. In 2019, 
Saskatchewan had the third highest projected age-standardized PCa incidence rate (117.8 cases 
per 100,000 in 2019) when compared to other Canadian provinces (1). In addition, the 
Saskatchewan age-standardized PCa incidence rates have remained higher than the national 
Canadian rates for the majority of the past 10 years (1, 2). Previous studies have shown 
geographic factors influence PCa outcomes in Saskatchewan (3, 4), hence this study explores the 
influence of geographic patterns on PCa incidence rates in Saskatchewan.  
Saskatchewan, in terms of geography, has the second lowest population density in 
Canada (after Newfoundland), with a majority of the province being sparsely populated and 
nearly 40% of the Saskatchewan population living in rural areas (5). Because cancer patient 
outcomes are worse for rural dwellers compared to urban dwellers (6-10) and Saskatchewan has 
a relatively large rural population (5), it is possible that the rates for different PCa risk levels are 
associated with the geographic distribution of Saskatchewan residents. 
The low population density of Saskatchewan results in the geographic factors of 
remoteness and commute time being healthcare access barriers for Saskatchewan residents (3, 4, 
11, 12). The low population density also impacts the distribution of physicians in the province. 
Saskatchewan has one of the lowest per capita physician supplies (also known as physician 
density) compared to the other provinces in Canada (190.3 per 100,000 in 2014 and 204.5 per 
100,000 in 2018) (13). Because one mechanism for improving health outcomes, including 
reductions in PCa-specific mortalities, is increasing physician supply (14-20), understanding the 
associations (if any) between physician density and PCa risk level incidence is crucial to 
improving PCa outcomes in Saskatchewan. 
While the factors leading to such high Saskatchewan PCa incidence rates are unknown, 
we hypothesize that the unique geography of Saskatchewan may be contributing to the high 
incidence of PCa in Saskatchewan. In this study we explore the geographic distribution of PCa 
cases in Saskatchewan. In addition, since the incidence for advanced cancers is known to 
decrease with the increase in availability of physicians (18, 21, 22), we identify the association 
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(if any) that exists between the family physician density and PCa standardized incidence ratios 
(SIRs) in Saskatchewan. 
The first study objective is to estimate the PCa SIRs in Saskatchewan stratified by PCa 
risk levels. The second objective is to identify clusters of higher than and lower than expected 
PCa SIRs in Saskatchewan stratified by PCa risk level. The final objective is to identify any 
associations between family physician density and the estimated PCa SIRs in Saskatchewan. 
3.2. Methods 
3.2.1. Data and Study Area 
The data for PCa were from the Saskatchewan Cancer Registry (SCR) and consisted of 
demographic, clinical, and geographic information for 3,526 patients diagnosed with PCa 
between 2010 and 2014. Based on the demographic information, all PCa patients were age 35 
years or over. The study area contained 82 geographic areas (GAs) in central and southern 
Saskatchewan categorized (for privacy reasons) by the SCR using residence codes (Figures 3.1 
and 3.2) (23). From 2010 to 2014, the study area contained 3,289 PCa patients, after excluding 
those living out-of-province at the time of diagnosis (194 patients) and those (43 patients) living 
in the three northern regions (Mamawetan Churchill River, Keewatin Yatthe, and Athabasca). 
The northern regions were excluded because these regions could not be subdivided due to 
privacy reasons. Of these 3,289 PCa patients, the analysis further excluded 298 patients because 
their PCa risk levels were unknown. Therefore, the final sample had 2,991 patients, each 
categorized per the GA in which the patient lived at the time of diagnosis.  
To calculate the SIRs (described in the following sections), population counts for 2012 
from the Saskatchewan Covered Population (SCP) were used in the denominator in the formula 
for calculating a PCa SIR (see Definitions section) (23). The SCP is a count of residents with 
provincial health insurance in Saskatchewan in a given year and is maintained by Government of 
Saskatchewan (23). Because all PCa patients in the SCR dataset were age 35 or over, the SCP 
data used were for men over the age of 35. The overall SCP for men age 35 or over deviated less 
than 3% each year (24), therefore we chose to use statistics from the midpoint year 2012 
(between 2010 and 2014) for the denominators in the calculations (25).  
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To calculate physician density (described in the following sections) for the period 2010 to 
2014, the required data from the Canadian Medical Association were only available for 2011 
(26). Hence our estimated physician densities are based on the year 2011. Canadian Medical 
Association data consist of family physicians and general practitioners licensed to practice 
medicine in Saskatchewan.  
The relative variability of PCa incidence between the time period (2010 to 2014) was 
assessed using the coefficient of variation (ratio of the standard deviation to the average). 
The University of Saskatchewan BioMedical Research Ethics Board provided ethics 
approval (Bio-REB certificate #15-34).  
3.2.2. Definitions 
The risk levels (low, intermediate, high) for PCa were based on the Genitourinary 
Radiation Oncologists of Canada (GUROC) definitions (27) and a fourth risk level (“metastatic”) 
was added to include patients diagnosed with metastatic cancer. For each risk level, the expected 
number of PCa cases in the ith GA (Ei) was calculated as follows (28): 
 !" = $" %&& '&& ,     (3.1) 
where ni and Oi respectively denote the population count of men age 35 or over and the observed 
number of PCa cases in the ith GA. For each PCa risk level, the standardized incidence ratio 
(SIR) (which will be referred to as the crude estimated SIR) was estimated by dividing the 
number of observed cases in each GA by the number of expected cases in each GA (28). 
3.2.3. Independent Variables 
The study variables of interest were physician density, GA remoteness index, and closest 
PCa assessment centre to a GA. For each GA, the family physician density was calculated using 
the 2011 Canadian Medical Association data, with the same population denominator used for the 
expected count of PCa cases. A remoteness index for a GA was calculated using the average of 
the Statistics Canada remoteness indices for regions forming the GA [29]. For each GA, the 
closest PCa assessment centre was categorized as Regina or Saskatoon, based on the shortest 
Euclidean distance between the centroid of the GA and the centroids of Saskatoon and Regina. 
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Further details regarding GA remoteness index and closest PCa assessment centre variables used 
in this study can be found in the literature (3, 4). 
3.2.4. Statistical Methods 
Clustering analysis was conducted to identify spatial clusters of PCa SIRs by each risk 
level. Second, for each PCa risk level, a null model was built where the crude estimated SIRs 
were smoothed spatially using the method proposed by Besag, York and Mollie (BYM model) 
(29).  The estimated SIRs from the BYM models will be referred to as the smoothed estimated 
SIRs. Third, ecological analyses were conducted to assess any associations between the 
independent variables and the smoothed estimated SIRs for each of four PCa risk levels.  
3.2.5. Clustering Analysis 
For each risk level, Global Moran’s I was calculated using the crude estimated SIR value 
for each GA (30). The statistical significance for Global Moran’s I statistic was calculated using 
999 permutations (30), which, if significant, demonstrates that the GAs sharing common 
boundaries have similar SIRs instead of having random geographically-distributed SIRs (31). 
GAs within a 120-km radius of a GA were identified as neighbours of the GA. The 
corresponding weight matrix for the analysis was then computed using the inverse of the 
Euclidean distances between the centroids of a GA and its neighbours.  This weight matrix was 
chosen to reflect the suspected correlation structure of the data (32).  
For each risk level with statistically significant Global Moran’s I values, the crude 
estimated SIRs were studied further using the Local Moran’s I and Kuldorff’s Spatial Scan 
statistics (33-35).  
3.2.6. BYM Modeling 
The SIRs were estimated using a Bayesian model-based approach to ensure, if spatial 
correlation exists, the estimated SIRs (i.e., the smoothed estimated SIRs) were corrected for any 
spatial dependence between the GAs.  
First, for each PCa risk level, a null model was built where the smoothed estimated SIRs 
were computed using the Bayesian BYM method (29). Due to the count nature of the data, we 
assume our observed data Oi follows a Poisson distribution (36) with mean Eiqi where Ei and qi 
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respectively denote the expected number of PCa cases and the “true” SIR in the ith GA (37, 38). 
The BYM method models the log of the SIR as follows:  
 Log(qi) = c + ui + vi, (3.2) 
where intercept c is the mean, and the terms ui and vi respectively denote the spatially structured 
and unstructured random effects (37, 38). 
The parameters used in this model are based on the literature (37-41). The random effects 
and the intercept are assigned prior distributions. The intercept was assigned a uniform prior that 
extends over the whole real line (37, 38). The spatially structured random effect ui was assumed 
to follow a conditional auto-regressive distribution and the unstructured random effect vi was 
assumed to follow a normal distribution with mean zero (37, 38). The variability for both random 
effects were controlled by a precision parameter. The precision parameter for the random effects 
were assigned a Gamma distribution with hyper-prior specification of (0.5, 0.0005)  (39, 41). 
The simulation for each model consisted of three chains (42, 43). Each chain consisted of 
200,000,000 iterations to obtain 50,000 data points: one taken every 4000 iterations. A burn-in 
period of 8,000,000 iterations was selected based on the characteristics of the Brooks-Gelman-
Rubin plots (38, 42, 43). To determine whether the generated estimates for each parameter were 
from the correct distribution, the following were used: potential scale reduction factor, (42) 
stationarity and half-width tests, (44) Z-score for equality of the means, (45) and run length 
control (46, 47)).  
3.2.7. Ecological Analysis 
Using the BYM models, unconditional analyses were conducted to identify any 
associations between the independent variables and the SIRs for each risk level. The statistical 
significance of an independent variable was determined via its 95% credible interval (CrI).  
Global and Local Moran’s I statistics were computed using Geoda 1.12 (48). Kuldorff’s 
Spatial Scan Statistic was computed using SatScanTM v9.4 (49). SIR maps were built using 
quantum Geographical Analysis System (QGIS.org) Version 3.12 (50). BYM models were built 
in OpenBUGS version 3.2.3 (51). Convergence diagnostics for the BYM models were conducted 
in R using the package ‘coda’ (52). 
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3.3. Results 
The study sample consisted of an average count of 598 PCa cases per year between 2010 
and 2014, and the coefficient of variation for PCa incidence between 2010 and 2014 was 7.9%. 
During the five-year period, the coefficient of variation for remoteness index and physician 
density were 1.4% and 5.0%, respectively. Based on the age demographic information of all 
cases, a majority of the PCa cases were 70 years or older, followed by those who were 60 to 69 
years old (Table 3.1). However, the distribution of the age demographics varied by risk level. 
Low and intermediate risk PCa cases had higher proportions of cases in the younger age groups. 
In contrast, high risk and metastatic cases had higher proportions of cases in the older age 
groups. Among all cases, each year (between 2010 and 2014) the proportion of cases diagnosed 
was about 20% with deviations of less than 2%.  See Table 3.1 for details. 
Table 3.1. Descriptive statistics of the prostate cancer cases stratified by GUROC risk levels (n=2991). 
Count (proportion) Metastatic High Risk Intermediate Low Risk Total 
Age      
< 60 years 27 (6.7) 168 (15.4) 277 (26.2) 118 (26.6) 590 (19.7) 
60 to 69 years 87 (21.6) 393 (36.1) 458 (43.4) 224 (50.5) 1162 (38.9) 
70 years or older 288 (71.6) 528 (48.5) 321 (30.4) 102 (23.0) 1239 (41.4) 
Year of diagnosis      
2010 81 (20.2) 193 (17.7) 206 (19.5) 84 (18.9) 564 (18.9) 
2011 73 (18.2) 252 (23.1) 211 (19.8) 104 (23.4) 640 (21.4) 
2012 58 (14.4) 223 (20.5) 265 (25.1) 113 (25.5) 659 (22.0) 
2013 89 (22.1) 213 (19.6) 197 (18.7) 66 (14.9) 565 (18.9) 
2014 101 (25.1) 208 (19.1) 177 (16.8) 77 (17.3) 563 (18.8) 
Total 402 (100.0) 1089 (100.0) 1056 (100.0) 444 (100.0) 2991 (100.0) 
 
The highest proportion of cases were high-risk PCa (36.4%) followed by intermediate-
risk (35.3%), low-risk (14.8%) and metastatic cases (13.4%). In nearly a third of GAs (32.9%), 
the observed incidence of metastatic PCa was more than 50% than the expected incidence. In 
28%, 18% and 24% of GAs, the observed incidences of high-risk, intermediate-risk and low-risk 
PCa, respectively, were more than 50% than the expected incidence. See Table 3.2 for details. 
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Table 3.2. Descriptive statistics of prostate cancer cases diagnosed within each geographic area (82 
areas). 
 Metastatic High Risk Intermediate Low Risk 
Crude estimated SIR     
>50% less than expected 21 areas 9 areas 16 areas 24 areas 
10% to 50% less than expected 15 areas 25 areas 23 areas 17 areas 
Within 10% expected 10 areas 12 areas 9 areas 6 areas 
10% to 50% more than expected 9 areas 13 areas 19 areas 15 areas 
50% to 100% more than expected 15 areas 13 areas 7 areas 8 areas 
>100% more than expected 12 areas 10 areas 8 areas 12 areas 
 
3.3.1. Clustering Analysis  
The pattern of crude estimated SIRs for each PCa risk level in Saskatchewan is visualized 
in Figure 3.1. Spatial patterns within Figure 3.1 are identified using clustering analysis. The 
Global Moran’s I statistics for the crude estimated SIRs for each PCa risk level (except for high-
risk) show evidence of positive spatial autocorrelation (Table 3.3). Hence, there was evidence 
that some geographical areas in Saskatchewan sharing boundaries have similar crude estimated 
SIRs for metastatic, intermediate and low risk PCa, instead of a random distribution of incidence 
patterns.  
Table 3.3. Result of the Global and Local Moran’s I analysis stratified by GUROC risk levels. 
 Metastatic High Risk Intermediate Risk Low Risk 
Global Moran’s I statistic 0.132* 0.058 0.128* 0.106* 
Local Moran’s I      
High-High 4 areas - 8 areas 2 areas 
Low-Low 9 areas - 13 areas 15 areas 
Low-High 4 areas - 0 areas 4 areas 
High-Low 4 areas - 2 areas 1 area 
Not Significant 61 areas - 59 areas 60 areas 
*statistically significant at 5% level of significance 
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Figure 3.1. Crude estimated standardized incidence ratios (SIRs) for metastatic, high-risk, 
intermediate-risk, and low-risk prostate cancer cases in Saskatchewan (2010 to 2014). 
 
  37 
Using the Local Moran’s I statistic, clusters of crude estimated SIRs for each PCa risk 
level were identified.  In Figure 3.2, “high-high” clusters of metastatic PCa are identified in the 
north-east part of the study area. Hence, areas in north-east Saskatchewan have higher-than-
average crude estimated SIRs for metastatic PCa. For intermediate-risk and low-risk PCa, “low-
low” clusters are identified in the north-west part of the study area. Therefore, areas in north-
west Saskatchewan have lower-than-average crude estimated SIRs for both intermediate-risk and 
low-risk PCa (Figure 3.3 and Figure 3.4). 
For Kuldorff’s Spatial Scan Statistic, the maximum spatial window size for metastatic, 
intermediate and low risk PCa were equal to or less than 30%, 25% and 25%, respectively, of the 
total population. Kuldorff’s Spatial Scan Statistic identified a higher-than-the-average cluster of 
crude estimated SIRs for metastatic PCa in north-east Saskatchewan and lower-than-the-average 
cluster in south-east Saskatchewan, analogous to the clusters identified using the Local Moran’s I 
statistics (Figure 3.2). Similarly, the spatial scan statistic results for intermediate-risk and low-
risk PCa were comparable to the clusters identified using the Local Moran’s I statistics described 
earlier (Figure 3.3 and Figure 3.4). 
3.3.2. BYM Modeling 
The crude and smoothed estimated SIRs for a GA are illustrated in Figure 3.5.  For both 
metastatic and high-risk PCa, the smoothed BYM estimates highlight areas of elevated incidence 
in north-east part of Saskatchewan (Figure 3.5). Also in Figure 3.5, the smoothed estimated SIRs 
for intermediate-risk and low-risk PCa identify areas of low incidence in north-west part of 
Saskatchewan. Table 3.4 illustrates how the crude estimated minimum and maximum SIR values 
are adjusted by the BYM modelling.  
Table 3.4. Comparison of minimum and maximum values of smooth estimated standardized 
incidence ratios (SIRs) and crude estimated SIRs stratified by GUROC risk levels. 
 Crude estimated SIRs Smoothed estimated SIRs 
Outcome Min Max Min Max 
Metastatic 0.000 3.474 0.921 1.221 
High Risk 0.213 3.633 0.883 1.218 
Intermediate Risk 0.000 5.888 0.347 3.093 
Low Risk 0.000 4.470 0.235 2.348 
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Figure 3.2. Metastatic prostate cancer crude estimated SIRs clustering analysis: (A) Local 
Moran’s I; (B) Kuldorff’s Spatial Scan Statistic. 
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Figure 3.3. Intermediate-risk prostate cancer crude estimated SIRs clustering analysis: (A) 
Local Moran’s I; (B) Kuldorff’s Spatial Scan Statistic. 
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Figure 3.4. Low-risk prostate cancer crude estimated SIRs clustering analysis: (A) Local 
Moran’s I; (B) Kuldorff’s Spatial Scan Statistic. 
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Figure 3.5. Quantile distribution of prostate cancer crude estimated SIRs (left) and 
smoothed estimated SIRs (right) by GUROC risk levels. 
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3.3.3. Ecological Analysis 
Family physician density was negatively associated with the smoothed estimated SIRs for 
metastatic PCa (IRR: 0.935 [CrI: 0.880 to 0.998]) and for high-risk PCa (IRR: 0.927 [CrI: 0.880 
to 0.975]). Based on the mean coefficient of family physician density for metastatic PCa (Table 
3.5), one unit increase (or increase of 1 physician per 1,000 population) would be equal to an 
average decrease in metastatic PCa SIR by 6.5%. Similarly, an average increase of 1 physician 
per 1,000 population would be equal to an average decrease in high-risk SIR by 7.3%. Figure 3.6 
provides geographic pattern of family physician density in Saskatchewan and comparison with 
Figure 3.5 visually complements the negative correlation with metastatic PCa and high-risk PCa. 
For intermediate-risk and low-risk PCa, based on the credible intervals, there was no evidence of 
association with family physician density (Table 3.5).  
 
Figure 3.6. Quantile distribution of family physician density in Saskatchewan (2011). 
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Table 3.5. Result of the Bayesian analysis proposed by Besag, York and Mollie (BYM method). 
 Physician Density (Number of physicians per 1,000 population) 
Outcome Mean Credible Interval 
Incidence Rate Ratio  
(Credible Interval) 
Metastatic -0.067 -0.128 to -0.002 0.935 (0.880 to 0.998) 
High Risk -0.076 -0.128 to -0.025 0.927 (0.880 to 0.975) 
Intermediate Risk -0.041 -0.109 to 0.026 Not significant 
Low Risk -0.009 -0.079 to 0.062 Not significant 
 
There was no evidence of any association between the SIR of each PCa risk levels and 
the two remaining independent variables (closest PCa assessment centre to a GA and GA 
remoteness index).  
3.4. Discussion 
This study estimated risk stratified PCa SIRs in Saskatchewan to identify if any 
geographic patterns and disparities. The geographic patterns of the risk stratified SIRs identified 
areas of concern (higher than expected SIRs) in Saskatchewan using Bayesian models and 
traditional clustering analysis methods. This study found clustering of higher than expected 
incidence for metastatic PCa in north-east part of Saskatchewan, and lower than expected 
incidence in south-east part of Saskatchewan. This study also identified lower than expected 
incidence of intermediate-risk and low-risk PCa in the north-west part of Saskatchewan. The 
estimation of SIRs using the BYM method led to adjustment of the crude estimated SIRs to 
facilitate identification of spatial trends (53).  
Our study also shows that areas with lower density of family physician have higher than 
expected incidence of metastatic and high-risk PCa. A similar trend has been observed in the 
United States where increases in primary care physician density were associated with a decrease 
in late-stage diagnosis of cancers including PCa (21, 54). The findings of this study highlight the 
effect that increasing physician supply may have on improving health outcomes, as identified in 
previous studies including PCa (14-20). The results also highlight the wide-ranging distribution 
of family physicians within Saskatchewan, acknowledging Saskatchewan also has one of the 
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lowest per capita physician supplies compared to the other provinces in Canada (13). Hence, 
policies to increase physician supply should ensure equitable geographic distribution of primary 
care physicians to support early detection of diseases including PCa.  
Nearly half of the patients in the sample were high risk (36.4%) or metastatic (13.4%), 
which could be indicative of physician practice variations including receptiveness towards PCa 
screening policies. Literature shows that physician beliefs regarding PCa screening/diagnosis 
procedures can influence their practice (physicians who are uncertain about PCa 
screening/diagnosis procedures are less receptive towards offering PCa screening/diagnosis to 
their patients) (55). Because such practice variations possibly exist among Saskatchewan 
physicians suggested by the historical PCa screening trends (56, 57) and the literature reports 
that an increase in advanced PCa may be due to a decrease in PCa screening (58), physician 
beliefs might possibly explain the geographic variations in PCa diagnosis rates.  
Although family physician density was not associated with diagnostic pattern for low-risk 
and intermediate-risk PCa, further research is needed if these regional trends are related to 
physician practices given the controversy of screening tests for early detection of PCa (59, 60). 
Given recent research showing PCa screening and detection of early-stage PCa decreasing, 
potentially due to mixed PCa screening guidelines, further studies assessing the role of PCa 
screening guidelines on geographic disparities in early-stage PCa incidence may provide further 
explanation (61). 
This study identifies the geographical disparities in risk-stratified PCa incidence in 
Saskatchewan. This study suggests that healthcare access factors (62), including availability of 
physicians and the geographic location of individuals, may affect health outcomes for PCa. This 
study further highlights the possibility that enhancing health delivery in rural areas may improve 
health outcomes.  A recent report by the Rural Road Map Implementation Committee in Canada 
shows there are continued challenges regarding healthcare access in rural parts of Canada, 
including difficulties of attracting and retaining physicians (63). 
The limitations of this study include the use of aggregate data for the ecological study 
design due to lack of information on individual-level data on family physician availability to the 
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patient. However, the study uses widely developed Bayesian and conventional spatial analysis 
methods to identify inherent patterns in the study area. 
3.5. Conclusions 
This study identified geographic disparities in PCa incidence in Saskatchewan. There 
were higher than expected incidence of metastatic PCa in north-east parts of Saskatchewan, and 
lower than expected incidence of intermediate-risk and low-risk PCa in the north-west part of 
Saskatchewan. In addition, areas with lower density of family physician had higher than 
expected incidence of metastatic and high-risk PCa. This study shows that availability of 
community level healthcare providers and geographic location of patients affects cancer care in 
Saskatchewan. This highlights the need for adequate availability of primary care physicians in 
rural and urban areas to improve cancer care in Saskatchewan.  
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CHAPTER 4 – THE IMPACT OF GEOGRAPHIC LOCATION ON SASKATCHEWAN 
PROSTATE CANCER PATIENT TREATMENT CHOICES: A MULTILEVEL AND 
SPATIAL ANALYSIS 
Article reproduced with permission and minor edits. Originally published as: Andkhoie 
M, Szafron M. The impact of graphic location on Saskatchewan prostate cancer patient treatment 
choices: a multilevel and spatial analysis. J Rural Health. 2020; 36(4): 564-576; 
https://dx.doi.org/10.1111/jrh.12471. My contributions to this study include data acquisition, 
study design, data analysis, interpretation of findings and manuscript preparation. 
In this chapter, we present the complete study used to address the research question “Are 
the PCa treatment utilization rates in Saskatchewan affected by changes in the remoteness level 
of where a patient lives and the closest PCa assessment centre from where a patient lives?” 
associated with our first study objective “to determine the associations (if any) between 
components of healthcare access and each of PCa incidence, treatment usage and time-to-
treatment trends among Saskatchewan patients”. Specifically, in this chapter we estimate the 
relationship between remoteness and the initial chosen treatment: active surveillance/watchful 
waiting (AS/WW), radiation therapy (RT), surgery, chemotherapy (CT), or hormonal therapy 
(HT) for prostate cancer (PCa). We built 2 multilevel generalized linear models via a binomial 
link for each treatment type (one with only covariates and one with 2 study variables added to 
the covariate model). In addition, we also used cluster analysis using the Global and Local 
Moran's I spatial statistics to find any complementary results to the above models. We found that 
patients living in the rural areas have lower odds (OR = 0.59; 95% CI, 0.45-0.77; P < 0.001) of 
having surgery compared to patients living in the greater urban areas. Among patients whose 
closest PCa assessment centre is Regina, patients living in the greater urban areas have higher 
odds (OR = 1.66; 95% CI, 1.03-2.68; P = 0.039) of choosing RT compared to patients living in 
the rural areas. There was no statistically significant effect of remoteness on whether one chose 
HT or AS/WW. There are regional disparities in PCa treatment utilization. Living in rural areas 
affects choosing surgery and, in certain localized geographical regions, affects choosing RT. For 
non-curative treatments (i.e., AS/WW and HT), we did not find any association with 
geographical remoteness. 
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4.1. Introduction 
In Canada, prostate cancer (PCa) is the second leading cause of cancer among men (after 
lung cancer) with approximately 1 in 8 males diagnosed in their lifetime (1). While the Canadian 
5-year relative PCa survival rate is 96%, the rates vary among the provinces, with Saskatchewan 
ranking second lowest (91%) (1). According to a 2015 national report, Saskatchewan also had 
the second highest (26 deaths per 100,000) age-standardized PCa mortality rate (1).  While each 
Canadian province individually administers PCa treatments and approved treatments are 
available at no charge through Canada’s universal health care system, it is unknown why 
Saskatchewan has these poor PCa outcomes (when compared to other provinces) (2). 
In Canada, rural and remote areas are known to face access barriers to health care 
services, including the availability of health care providers and long travel distances to health 
care facilities (3-6). In addition, transportation issues further add barriers to patients’ treatment 
decisions in rural regions (7). Multiple studies have shown that patients living in rural regions 
may compromise their cancer treatment decision, notably due to longer travel time and distance 
to access treatment centres (8-14). Because Saskatchewan has a relatively large rural population, 
Saskatchewan PCa patients living in rural geographic locations may face these issues regarding 
accessibility to health care services including cancer treatments (3-6, 15). Hence PCa patients 
might choose their PCa treatments based on where they reside rather than the optimal treatments 
available for their PCa pathology.  
In this work we explore the relationship between where Saskatchewan PCa patients 
reside and their treatment utilization, where the treatment choices include active 
surveillance/watchful waiting (AS/WW), surgery, radiation therapy (RT), chemotherapy (CT), 
and hormonal therapy (HT) (16). Studies show that rural patients have lower utilization for 
cancer treatments including for breast and lung cancers, but not consistently for PCa treatments 
(8, 11, 13, 17, 18). It is not known whether any relationship exists between geographic 
remoteness and PCa treatment utilization in Saskatchewan. We hypothesized that those living in 
rural areas would have higher non-curative treatment utilization (i.e., AS/WW and HT), and 
those living in urban areas would have higher curative treatment utilization (i.e., RT, CT, and 
surgery).  
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4.2. Methods 
4.2.1. Data 
Data for PCa patients diagnosed during 2010 through 2014 were sourced from the 
Saskatchewan Cancer Registry, a database of cancer health information (including treatment-
related information) for cancer patients diagnosed in Saskatchewan. While the Registry 
contained information for 3,526 PCa patients diagnosed during the study period, the final sample 
used consisted of 3,289 patients (93.3%), after excluding patients living out-of-province at the 
time of diagnosis (194 cases) and those (43 cases) living in the 3 former northern health 
authorities (Mamawetan Churchill River, Keewatin Yatthe, and Athabasca). Those living in the 
northern health authorities were excluded because for privacy reasons these health authorities 
could not be subdivided into smaller geographic areas (GAs). The University of Saskatchewan 
BioMedical Research Ethics Board provided ethics approval (Bio-REB certificate #15-34).  
4.2.2. Variables 
For each of the treatments—surgery, RT, HT, or CT—we derived a corresponding 
variable coded as “Yes” if, after PCa diagnosis, a patient received the treatment within 2 years 
after their diagnosis date, or “No” otherwise. For AS/WW, we derived a variable coded as “Yes” 
if a patient did not undergo any of these 4 treatments within 2 years after PCa diagnosis, or “No” 
otherwise. The “within 2 years” treatment definition is adapted from the radiation therapy 
utilization definition developed by Canadian Partnership Against Cancer (19). Patients may get 
multiple treatments within 2 years of diagnosis; therefore, surgery, HT, CT, or RT are not 
mutually exclusive. For HT, only drug-based treatments were captured (i.e., this excludes 
orchiectomy).  
For privacy reasons, the Saskatchewan Cancer Registry subdivided central and southern 
Saskatchewan into 82 GAs using residence code boundaries (see Figure 4.1) (20). The Census 
Metropolitan Areas (CMAs) of Saskatoon and Regina were 2 of these GAs. Each of the 3,289 
patients was categorized according to the GAs in which the patient lived at the time of diagnosis. 
To quantify how rural a GA was, we derived a remoteness score for each GA as the average of 
the Statistics Canada remoteness indices that were assigned to the residence code boundaries 





Figure 4.1. The geographic distributions for each of the variables of interest: (A) closest PCa assessment centre to a GA, and 
(B) GA remoteness index.
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forming the GA (21). The GA remoteness index accounts for the following 2 factors: population 
size and proximity to all population centres (21). 
For each GA, we defined its GA remoteness index as “greater urban area,” “intermediate 
remote,” or “rural” depending on whether the remoteness score of the GA was less than 0.35, 
0.35 to less than 0.40, and 0.40 or more, respectively (21). The criteria are based on the range 
provided for CMAs and small-size geographies from Statistics Canada remoteness indices (see 
Figure 4.1) (21). “Greater urban area” consists of Saskatoon and Regina (which have the 
treatment centres), and their immediate surrounding areas (a GA remoteness index less than 
0.35) (21). Geographic regions labeled “intermediate remote” generally consists of smaller cities 
in the study areas. “Rural” generally consists of GAs (with a GA remoteness index above 0.40) 
with no small or large city (21). 
For each patient, we defined the “closest PCa assessment centre to a GA” in 
Saskatchewan as Regina or Saskatoon, based on the minimum Euclidean distance between the 
centroids of the GA of the patient and the 2 cities (see Figure 4.1). 
In each model we controlled for the following factors: age at diagnosis, year of diagnosis, 
risk levels as defined by the Genitourinary Radiation Oncologists of Canada (GUROC), and 
other treatment types (except in the AS/WW model) (22). Patients with metastatic cancer and 
those who could not be assigned a GUROC risk level were respectively categorized as 
“metastatic” and “unknown.”  Refer to Table 4.1 and Table 4.2 for a summary of the outcome 
variables, study variables, and covariates. 
4.2.3. Statistical Methods 
Due to the small sample size, we were unable to develop models for CT treatment 
utilization. For each of the other 4 treatment outcomes -- AS/WW, RT, Surgery, and HT -- we 
developed 2 multivariable models as follows. 
4.2.3.1. Covariate Models 
For each treatment outcome, a multilevel generalized linear model using a binomial link 
was developed. Using manual backward elimination, we formed the “covariate model” which 
only contained factors that were statistically significant or confounding. Hence we assessed if 
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there is any relationship between each of the factors we are studying and each of the treatments. 
A statistical significance of a factor means it is associated with the given PCa treatment 
utilization behavior. The covariate model, for each treatment outcome, was the one with the 
lowest Akaike’s information criterion (AIC) value; alpha was set at 0.05 (23). The confounding 
effect was assessed using a 10% change in the estimated effects of the other independent 
variables (24). 
Each covariate model used the GAs of where patients reside as the random intercept. The 
value of the random intercept for each GA was used to estimate the proportion of variation 
unexplained by the factors (25, 26). The effect of where people live (i.e., the random intercept) 
on the treatment choice was estimated using the intraclass correlation (ICC) (25, 27). Model 
diagnostics performed comprised: assessing the group-level residuals for any deviation from 
normality, assessing the outliers of the models using deviance residuals, and assessing the 
sensitivity and specificity of the models using receiving operating characteristic (ROC) curves. 
4.2.3.2. Clustering Analysis 
Geographical clustering analysis was conducted using the group-level residual values for 
each GA from the covariate models (26). This clustering analysis was conducted to assess 
whether patients within a GA chose a particular treatment more than (or less than) the patients 
living in the neighbouring GAs. The clustering analysis included assessing the existence of 
spatial autocorrelation using Global Moran’s I, and smaller geography clusters were identified 
using Local Moran’s I. The statistical significance for Global Moran’s I was calculated using 999 
permutations. If significant, it means that the GAs sharing common boundaries have similar 
group-level residual values or similar treatment utilization trends instead of random geographical 
distribution of treatment utilization behavior (26, 28). An inverse distance-based neighbourhood 
spatial weight matrix with a 120-km cutoff was used to identify local clusters. This weight 
matrix was chosen to reflect the suspected correlation structure of the data (29). The weight 
matrix identifies which GAs are neighbours.  
4.2.3.3. Full Models 
For each treatment, the full model was formed by adding the 2 study variables (GA 
remoteness index and closest PCa assessment centre to a GA) to the covariate model. This 
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analysis would tell us whether GA remoteness index and closest PCa assessment centre to a GA 
were associated with a given treatment utilization behavior, after controlling for other individual 
factors. The same model building methods and diagnostics described for the covariate models 
(i.e., step 1) were applied to the full models. The effects of the 2 study variables were compared 
with the clusters identified in step 2 for any complementary trends. Two-way interaction between 
the variables of interest (GA remoteness index and closest PCa assessment centre to a GA) was 
explored in all 4 models. 
The multilevel models were built in Stata/IC 15.1 for a Mac (StataCorp LLC, College 
Station, Texas) using the melogit command with the mvaghermite integration method using 
12 integration points. The Euclidean distances to the nearest CMA were determined using 
quantum Geographical Analysis System (QGIS.org) Version 3.4.0-Madeira. Global and Local 
Moran’s I tests were conducted using Geoda 1.12.1.129 (Center for Spatial Data Science, 
University of Chicago, Illinois). 
4.3. Results  
4.3.1. Descriptive Statistics 
Among all patients, the largest proportions were 60 to 69 years old (38.0%) and 70 to 79 
years old (26.8%). In terms of risk levels, intermediate (32.1%) and high risk (33.1%) levels 
accounted for two-thirds of the cases. The closest PCa assessment centre to a GA for just over 
half (53.1%) of the patients was in the CMA of Regina. About a third (30.8%) of the patients 
were categorized as living in the intermediate or rural areas. The utilization of AS/WW at initial 
diagnosis was just over a quarter of the patients (27.3%). The utilization of RT (31.8%), surgery 
(30.6%), or HT (34.8%) treatments were each about a third of the patients (see Table 4.1 and 
Table 4.2 for further descriptive statistics). 
4.3.2. Covariate Models 
In all 4 models, the year of diagnosis was not statistically significant, increased the AIC 
values, and did not have a confounding effect. Hence a patient’s year of diagnosis did not 
influence the treatment they chose. The ICC for the random intercept was highest for the RT 
model (5.7%; P < 0.0001) followed by the AS/WW model (1.6%; P = 0.0006). The random 
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intercepts for the surgery (P = 0.1027) and HT (P > 0.9999) covariate models were not 
statistically significant. Hence the location of where patients reside may influence their RT and 
AS/WW treatment decisions, but not their surgery and hormone therapy decision. Ultimately, 
this is showing that location influences treatment choices. Next, using clustering analysis, we 
identified which areas in Saskatchewan were more likely to undergo RT and AS treatments. 
Table 4.1. Descriptive statistics of all variables in Chapter 4 (n=3289). 
Variable Count (%) Variable Count (%) 
Treatmentsa  Age groups  
RT 1046 (31.8) <60 624 (19.0) 
Surgery 1005 (30.6) 60 to 69 1250 (38.0) 
HT 1146 (34.8) 70 to 79 882 (26.8) 
AS/WW 899 (27.3) 80 or above 533 (16.2) 
GA Remoteness Index  Closest PCa Assessment Centre to a GA  
Greater Urban Area 2276 (69.2) Saskatoon 1542 (46.9) 
Intermediate 427 (13.0) Regina 1747 (53.1) 
Rural 586 (17.8)   
GUROC risk  Year of diagnosis  
Metastasized 402 (12.2) 2010 606 (18.4) 
High 1089 (33.1) 2011 710 (21.6) 
Intermediate 1056 (32.1) 2012 724 (22.0) 
Low 444 (13.5) 2013 622 (18.9) 
Unknown 298 (9.1) 2014 627 (19.1) 
aPatients may utilize more than 1 treatment within 2 years of diagnosis (between RT, surgery, 
and HT). 
 
4.3.3. Clustering Analysis 
The Global Moran’s I for the RT treatment shows evidence of positive spatial 
autocorrelation (Moran’s I = 0.327; pseudo P < 0.001). The Local Moran’s I shows “low-low” 
clusters (a group of GAs in which a given treatment is chosen less often than the average) and 
“high-high” clusters (a group of GAs in which a given treatment is chosen more often than the 
average). Overall, the RT treatment revealed high-high clusters near the CMA of Saskatoon and 
low-low clusters near the CMA of Regina (see Figure 4.2). There were also outliers in these 
high-high and low-low cluster regions known as “low-high” and “high-low.” The GAs with a 
lower-than-average uptake of a treatment that neighbour a GA with a higher-than-average uptake 
are called “low-high” whereas the vice-versa scenario is called “high-low.” Therefore, areas 
proximal to Saskatoon were more likely to utilize RT treatment. 
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The Global Moran’s I for the AS/WW treatment also showed evidence of positive spatial 
autocorrelation (Moran’s I = 0.091, pseudo P = 0.026). The cluster analysis for the AS/WW 
covariate model showed a reverse trend to that for the RT treatment, meaning high-high clusters 
near the CMA of Regina and low-low clusters near the CMA of Saskatoon (see Figure 4.2). 
Therefore, areas proximal to the CMA of Regina were more likely to utilize AS/WW treatment. 
Table 4.2. Measure of association between variables of interest and the covariates. 
 GA Remoteness Index Closest PCa Assessment Centre to a GA 
 Greater Urban Area Intermediate Rural Saskatoon Regina 
Age P = 0.052 P = 0.071 
<60 462 67 95 284 340 
60 to 69 860 164 226 598 652 
70 to 79 610 115 157 389 493 
80 or above 344 81 108 271 262 
GUROC risk P = 0.076 P < 0.001 
Metastasized 259 64 79 235 167* 
High 739 143 207 524 565 
Intermediate 756 125 175 501 555 
Low 308 51 85 163* 281 
Unknown 214 44 40 119* 179 
Year of 
diagnosis P =0.753 P = 0.319 
2010 429 76 101 280 326 
2011 501 89 120 320 390 
2012 484 97 143 354 370 
2013 429 88 105 279 343 
2014 433 77 117 309 318 
RT P = 0.047 P < 0.001 
Yes 721 119* 206 612 434* 
No 1555 308 380 930* 1313 
Surgery P < 0.001 P <0.001 
Yes 745 132 128* 422* 583 
No 1531 295 458 1120 1164 
HT P < 0.001 P < 0.001 
Yes 742* 162 242 629 517* 
No 1534 265 344* 913* 1230 
AS/WW P = 0.698 P < 0.001 
Yes 616 124 159 339* 560 
No 1660 303 427 1203 1187* 
Bold is more than expected 
* is less than expected 
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Since the random intercept for the surgery and HT models were not significant, their 
group-level residuals were not analyzed. 
4.3.4. Full Models  
Age and risk levels were strongly associated with each of the treatments (see Table 4.3 
for results). For the AS/WW and HT treatments, increase in age increased the odds of utilization 
for both treatments. In contrast, RT and surgery were most common among younger men (with 
lower odds as men get older). AS/WW, RT, surgery, and HT were most common among low-
risk, intermediate-risk, high-risk, and metastatic patients, respectively. The association between 
each of the treatments with age and risk levels are visualized in Figure 4.3.  
In the final models, the ICC for the random intercept was only significant for the RT 
model (1.5%; P = 0.0233). The random intercepts for the surgery (P > 0.9999), AS/WW (P > 
0.9999), and HT (P > 0.9999) full models were not statistically significant. 
4.3.4.1. Radiation Therapy 
The effect of GA remoteness index on RT treatment utilization depends on which PCa 
assessment centre the patient lives near (Saskatoon or Regina) (see Tables 4.4 and 4.5 for 
interaction results). Among patients whose closest PCa assessment centre to a GA was 
Saskatoon, those living in the greater urban areas had 2.07 (95% CI: 1.22-3.49; P = 0.007) times 
higher odds of RT treatment utilization compared to those living in the intermediate remote 
areas, but there was no difference in the RT treatment utilization between greater urban and rural 
areas (P = 0.307). Therefore, patients living in the intermediate remote areas were least likely to 
utilize RT treatment in the GAs where Saskatoon was the closest PCa assessment centre. Among 
patients whose closest PCa assessment centre was Regina, those living in the greater urban areas 
had 1.66 (95% CI: 1.03-2.68; P = 0.039) times higher odds of RT treatment utilization compared 
to those living in the rural areas. Hence patients living in the rural areas were least likely to 
utilize RT treatment in the GAs where Regina was the closest PCa assessment centre. Within the 
greater urban areas and rural areas, those patients whose closest PCa assessment centre was 
Saskatoon (compared to Regina) had 2.58 times (95% CI: 1.55-4.31; P < 0.001) and 1.89 times 
(95% CI: 1.36-2.65; P < 0.001) higher odds of RT treatment utilization, respectively. Therefore, 
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in both rural and urban areas, patients whose closest centre was Saskatoon were more likely to 
utilize RT treatment compared to patients whose closest centre was Regina. 
Table 4.3. Odds ratios (with confidence intervals) of independent variables in the full models. 
 AS/WW HT RT Surgery 
Age groups *** *** *** *** 
<60 0.21 (0.15-0.30)* 0.42 (0.28-0.63) * 10.27 (6.83-15.46)* 8.18 (5.82-11.48)* 
60 to 69 0.31 (0.23-0.41)* 0.62 (0.44-0.87) * 9.12 (6.30-13.18)* 5.19 (3.83-7.03)* 
70 to 79 0.41 (0.31-0.55)* 0.94 (0.68-1.30) 5.78 (4.02-8.30)* 2.07 (1.51-2.85)* 
80 or above Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
GUROC 
risk *** *** *** *** 
Metastasized 0.28 (0.20-0.41)* 61.57 (41.31-91.77)* 0.06 (0.04-0.09)* 1.14(0.76-1.71) 
High 0.33 (0.26-0.42)* 11.75 (8.83-15.63)* 0.55 (0.42-0.72)* 4.01 (3.14-5.12)* 
Intermediate Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
Low 7.83 (6.08-10.10)* 0.15 (0.08-0.27)* 0.34 (0.25-0.45)* 0.11 (0.08-0.16)* 
Unknown 3.07 (2.31-4.09)* 0.42 (0.20-0.87)* 0.06 (0.03-0.12)* 1.16 (0.86-1.58) 
RT - *** - *** 
Yes - 10.01 (7.64-13.10)* - 0.16 (0.12-0.20)* 
No - Ref. cat. - Ref. cat. 
Surgery - *** *** - 
Yes - Ref. cat. Ref. cat. - 
No - 6.17 (4.64-8.22)* 6.14 (4.70-8.03)* - 
HT - - *** *** 
Yes - - 9.68 (7.33-12.78)* 0.20 (0.15-0.26) 







index and closest 
PCa centre to a GA 
– see Table 4.4 and 




Urban Area Ref. cat. Ref. cat. Ref. cat. 
Intermediate 1.15 (0.87-1.52) 1.27 (0.92-1.75) 0.95 (0.73-1.25) 
Rural 1.14 (0.89-1.48) 1.27 (0.97-1.66) 0.59 (0.45-0.77) * 
Closest PCa 
assessment 
centre to a 
GA 
*   
Saskatoon Ref. cat Ref. cat Ref. cat. 
Regina 1.47 (1.17-1.84)* 0.96 (0.77-1.19) 0.96 (0.80-1.17) 
* P < 0.05  
*** P < 0.0001 
-  Not included in the model because not applicable




Figure 4.2. Cluster analysis (Local Moran’s I test) of group-level residuals for the covariate models using inverse distance 
weight with cut-off at 120 KM for: (A) active surveillance/watchful waiting treatment, and (B) radiation therapy treatment. 
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(a) (b) 
  
(c)  (d) 
  
Figure 4.3. Age and GUROC risk levels: Association to each of the treatment options (A) active surveillance/watchful waiting, 




























































































































Predicted Means (95% CI): Age groups and GUROC risk
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The effect of the random intercept on the RT model was estimated using the population-
averaged odds ratio (see Table 4.6). The population-averaged odds ratios did not statistically 
differ from the median odds ratios because of the small value of the ICC. 
4.3.4.2. Surgery 
Those who live in the rural areas had 0.59 (95% CI: 0.45-0.77; P < 0.001) times the odds 
of surgery treatment utilization compared to those living in the greater urban areas (see Table 
4.4). Hence patients living in rural areas were least likely to utilize surgery. In terms of the 
closest PCa assessment centre to a GA (Saskatoon or Regina), there was no difference in the 
odds of surgery treatment utilization among these 2 groups (P = 0.709). 
Table 4.4. Odds ratios (with confidence intervals) of interaction effect variables (remoteness index 
and closest PCa assessment centre) in the radiation therapy full model. 
 Coefficient (95% CI) OR (95% CI) P 
GA Remoteness Index   0.02 
Greater Urban Area Ref. cat. Ref. cat.  
Intermediate -0.73 (-1.25 to -0.20) 0.48 (0.29-0.82) 0.01 
Rural -0.19 (-0.57-0.18) 0.82 (0.57-1.20) 0.31 
Closest PCa Assessment 
Centre to a GA 
  < 0.01 
Saskatoon Ref. cat. Ref. cat  
Regina -0.64 (-0.97 to -0.30) 0.53 (0.38-0.74) < 0.01 
GA Remoteness Index x 
Closest PCa Assessment 
Centre to a GA 
 
 0.03 
Intermediate x Regina 0.77 (0.07-1.47) 2.17 (1.08-4.37) 0.03 
Rural x Regina -0.31 (-0.92-0.30) 0.73 (0.40-1.34) 0.32 
 
4.3.4.3. Active Surveillance or Watchful Waiting 
The effect of GA remoteness index on AS/WW treatment utilization was found to be not 
statistically significant. Therefore, AS/WW utilization rates did not change regardless of whether 
patients lived in rural or urban areas. However, those living closest to the Regina PCa assessment 
centre had 1.47 (95% CI: 1.17-1.84) times the odds of AS/WW treatment utilization compared to 
those living closest to the Saskatoon PCa assessment centre (see Table 4.4). Hence patients 
whose closest centre was Regina were more likely to utilize AS/WW compared to patients whose 
closest centre was Saskatoon. 
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Table 4.5. Select pairwise contrasts between GA remoteness index and closest PCa assessment centre 
to a GA for the radiation therapy full model. 
 Contrast (95% CI) OR (95% CI) P 
Greater Urban Area vs. Rural    
Closest PCa assessment centre – Regina 0.51 (0.02-0.99) 1.66 (1.03-2.68) 0.04 
Closest PCa assessment centre – Saskatoon 0.19 (-0.18-0.57) 1.22 (0.84-1.77) 0.31 
Greater Urban Area vs. Intermediate    
Closest PCa assessment centre – Regina -0.05 (-0.50-0.40) 0.95 (0.61-1.50) 0.84 
Closest PCa assessment centre – Saskatoon 0.73 (0.20-1.25) 2.07 (1.22-3.49) 0.01 
Intermediate vs. Rural    
Closest PCa assessment centre – Regina 0.55 (-0.01-1.12) 1.74 (0.99-3.06) 0.06 
Closest PCa assessment centre – Saskatoon -0.53 (-1.09-0.02) 0.59 (0.34-1.03) 0.06 
Closest PCa assessment centre –   Saskatoon 
vs. Closest PCa assessment centre - Regina 
   
Rural 0.95 (0.44-1.46) 2.58 (1.55-4.31) < 0.01 
Intermediate rural -0.13 (-0.74-0.47) 0.87 (0.48-1.60) 0.66 
Greater Urban Area Saskatoon vs Regina 0.64 (0.30-0.97) 1.89 (1.36-2.65) < 0.01 
 
Table 4.6. The effect of random intercept (median odds ratios and population average odds ratios) in 
the radiation therapy full model. 
 Coefficient Coefficient Odds Ratios Odds Ratios (Median) (Population Averaged) (Median) (Population Averaged) 
Age groups     
<60 2.33 2.31 10.27 10.07 
60 to 69 2.21 2.19 9.12 8.94 
70 to 79 1.75 1.74 5.78 5.69 
80 or above Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
GUROC risk level     
Metastasized -1.71 -1.69 0.18 0.18 
High 0.49 0.48 1.63 1.62 
Intermediate 1.09 1.08 2.97 2.94 
Low Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
Unknown -1.79 -1.77 0.17 0.17 
Surgery     
Yes Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
No 1.82 1.80 6.14 6.05 
HT     
Yes 2.27 2.25 9.68 9.49 
No Ref. cat. Ref. cat. Ref. cat. Ref. cat. 
 
4.3.4.4. Hormonal Therapy 
The effect of GA remoteness index on HT treatment utilization was found to be not 
statistically significant. In addition, there was no statistical difference in HT treatment utilization 
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among those living closest to Regina or Saskatoon PCa assessment centres. Hence both GA 
remoteness index and closest PCa assessment centre to a GA did not influence HT treatment 
utilization. 
4.4. Discussion 
This is first such study in Saskatchewan, of which we are aware, that investigates the 
relationship between closest PCa assessment centre to a GA, GA remoteness index, and 
treatment utilization for PCa. This study found that patients living in the rural parts of 
Saskatchewan have lower odds of choosing surgery compared to patients living in greater urban 
areas. While surgery may seem appealing to some patients living in rural areas due to the 
logistics of one-time travel, this study shows that patients living in rural areas are still less likely 
to undergo surgery (30). A similar trend has been observed in the United States and Australia 
where rural dwellers were less likely to undergo surgery for their PCa, which the authors of these 
studies attributed to the longer travel distance to the centralized urban treatment centres, access 
to health care providers, and the geographical differences in the management of patients (13, 14, 
31-34). Given that PCa surgery in Saskatchewan is also centrally administered in the CMAs of 
Regina and Saskatoon, living in rural parts of the study area may be a proxy for needing longer 
travel to the Saskatchewan PCa assessment centres (compared to greater urban areas) (35). 
Studies on rural patients in British Columbia (another western Canadian province) found that 
long distance to urban health centres was a substantial barrier for cancer care due to travel 
expenses (36, 37). Other personal factors that may influence decisions for rural patients include 
rural cultures and attitudes of feeling marginalized in urban health care centres, and consequently 
avoiding treatments (7). 
For the RT treatment option, the effect of urban-rural disparity depends on the closest 
treatment centre for the patients. Among rural patients that had Saskatoon as their closest PCa 
assessment centre, there was no difference in choosing RT compared to the greater urban area. 
However, there is a cluster of patients living in the “intermediate remote” region that have 
Saskatoon as their proximal PCa assessment centre with lower odds of undergoing RT than 
patients living in the greater urban area. This study also found that the odds of choosing RT to be 
much greater among those whose closest PCa assessment centre was Saskatoon compared to 
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Regina (for both rural and urban areas). In the literature, the findings are mixed as well; whilst in 
British Columbia there was no difference in the utilization of RT between urban and rural PCa 
patients, in Ontario and Australia, studies from the late 1990s found RT treatment utilization was 
more common in areas near the treatment centres than those areas that were farther away (8, 38, 
39). A possible reason for lower odds of RT treatment among rural patients that have Regina as 
their closest PCa assessment centre could be due to the burden of daily travel over several weeks 
that is needed for RT (30). Other possible reasons identified in Canada could be the perceptions 
of long waits for RT, leading to either patients refusing treatment or physicians not making 
referrals (40). In addition, patients living in rural areas may have less access to specialists with 
adequate knowledge of RT treatments (8). The difference in RT treatment utilization between 
Saskatoon and Regina regions may possibly be due to difference in AS/WW trends (discussed in 
the next paragraph). 
This study found that patients whose closest PCa assessment centre was Regina have 
higher odds of choosing AS/WW compared to Saskatoon. The spatial analysis shows 
complementary results, with clusters in southern Saskatchewan near the CMA of Regina. If 
AS/WW is considered as a treatment option to delay curative treatment, this could suggest that 
patients in certain parts of southern Saskatchewan might be delaying their curative treatment 
more than in the GAs where Saskatoon is the closest PCa assessment centre. Comparing the 
AS/WW results to the RT results, we find that the region with higher odds for AS/WW is the 
same region with lower odds for RT (GAs whose closest PCa assessment centre is Regina). 
These disparities may be due to different physician practices or possible health access issues that 
are unique to the southern and central regions of Saskatchewan. Further research is required to 
identify the underlying reasons for the regional disparities for RT utilization in Saskatchewan. 
For HT, there was no difference in choosing HT regardless of the closest PCa assessment centre 
to a GA or the GA remoteness index. A study in the United States also showed no difference in 
AS/WW and HT utilization between rural and urban dwellers, similar to our study (41). This 
may be due to the availability of HT treatment (medication) because medications could be 
directly mailed to the patients.  
In terms of individual factors that were controlled for, this study shows older age and 
low-risk PCa are associated with increased odds of choosing AS/WW. AS/WW is a non-curative 
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treatment, and other studies also show it is most common among patients who are older, have 
greater comorbidities, and have low-risk PCa (42, 43). The PCa treatment guidelines identify 
AS/WW as a suitable option for low risk PCa and patients with less than 10 years of life 
expectancy (44-46). For intermediate and high risk patients, RT is considered a suitable a 
suitable option or surgery may be considered for patients with greater than 10 years of life 
expectancy (44-46). The treatment guidelines identify HT as a standard of care for all metastatic 
PCa patients (44-46). Hence, the findings of this study also align with the treatment guidelines, 
which shows the use of AS/WW was most commonly among patients with low-risk PCa (44-46). 
Undergoing HT was most common among older men, those who also had RT treatment 
utilization, and those who had high risk or metastatic PCa. Since HT is considered to improve 
treatment outcomes for those who are high risk or metastatic, and if they are undergoing RT, the 
findings are promising and consistent with what we may expect (47-49). Given the highest odds 
of HT was among metastatic patients, the findings of this study show Saskatchewan treatment 
trends for metastatic PCa align with the treatment guidelines (44-46). For RT and surgery, the 
utilization was higher among younger men, which is consistent with findings in another study 
looking at age as a factor for treatment utilization trends in Canada (50). In addition, our study 
shows RT and surgery were most commonly administered among intermediate and high risk PCa 
patients, which is consistent with the treatment guidelines (44-46). This study also shows that 
patients who received RT treatment were also commonly treated with HT, which aligns with the 
treatment guidelines (44-46). Hence, this study shows that treatment use patterns (among 
Saskatchewan patients with different risk levels) align with the expected clinical treatment 
guidelines (44-46).  
The potential limitations of this study include the lack of information on other treatment 
decision factors, including patient preferences, that possibly influence treatment choice (51). 
Data on patient comorbidity were also not available. This study was not able to distinguish those 
who were on watchful waiting versus active surveillance due to the nature of the population-level 
data. Consequently, AS/WW may include individuals who were unmanaged for PCa treatment. 
For HT, the data only capture drug-based treatments.  
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4.5. Conclusions 
Overall, there are regional disparities for PCa treatment utilization in Saskatchewan. 
Living in rural and remote areas affects surgery treatment utilization and, in some geographical 
areas, affects RT. For non-curative treatments (i.e., AS/WW and HT), we did not find any 
association with geographical remoteness. However, we did find regional disparity for AS/WW 
depending on the closest PCa assessment centre for the patient’s geographical area. Further 
research is required to identify the underlying reasons for the regional disparities for surgery, RT, 
and AS/WW utilization in Saskatchewan.  
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CHAPTER 5 – GEOGRAPHIC FACTORS ASSOCIATED WITH TIME-TO-TREATMENT 
OUTCOMES FOR RADIATION THERAPY AMONG LOCALIZED PROSTATE CANCER 
PATIENTS IN SASKATCHEWAN 
Article reproduced with permission and minor edits. Originally published as: Andkhoie 
M, Szafron M. Geographic factors associated with time-to-treatment outcomes for radiation 
therapy among localized prostate cancer patients in Saskatchewan. J Cancer Policy. 2020; 26; 
https://doi.org/10.1016/j.jcpo.2020.100259. My contributions to this study include data 
acquisition, study design, data analysis, interpretation of findings and manuscript preparation. 
In this chapter, we present the complete study used to address the research question “Are 
the PCa time-to-treatment outcomes in Saskatchewan affected by changes in the remoteness 
level of where a patient lives and the closest PCa assessment centre from where a patient lives?” 
associated with our first study objective “to determine the associations (if any) between 
components of healthcare access and each of PCa incidence, treatment usage and time-to-
treatment trends among Saskatchewan patients”. Specifically, in this chapter we assess factors 
associated with ‘ready-to-treat’-to-treatment (RTTx) time and diagnosis-to-treatment time for 
radiation therapy (RT) among prostate cancer (PCa) patients. These factors include remoteness 
level of where patients live and the closest PCa assessment centre. Multivariable analyses were 
conducted using zero-inflated negative binomial and Poisson regression models for the RTTx 
and diagnosis-to-treatment times, respectively. RT diagnosis-to-treatment time is positively 
correlated with the remoteness-index (P < 0.001). RTTx time differences between the Saskatoon 
and Regina areas exist but only among intermediate and low-risk cases. Among all intermediate 
risk and low risk patients, those in the Saskatoon area had 1.76 (95% CI: 1.38, 2.25; P < 0.001) 
and 2.15 (95% CI: 1.16, 3.98; P = 0.015), respectively, times longer RTTx times compared to 
patients in the Regina area. Those patients living in the Saskatoon area had 1.08 (95% CI: 1.01, 
1.16; P = 0.035), 1.15 (95% CI: 1.04, 1.28; P = 0.009) and 1.64 (95% CI: 1.24, 2.16; P < 0.001) 
times longer RT diagnosis-to-treatment times compared to patients living in Regina area among 
high, intermediate and low risk patients, respectively. There was a decrease in diagnosis-to-
treatment time between 2011 and 2014 compared to 2010 (P < 0.001). We show that living in 
rural/remote areas is associated with delays for PCa RT. Both RTTx and diagnosis-to-treatment 
times for PCa RT were longer in localized regions in Saskatchewan where Saskatoon was the 
closest PCa assessment centre. There was a decrease in RT delays between 2010 and 2014 in 
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Saskatchewan. Policies addressing treatment delays should ensure localized strategies for 
rural/remote areas to reduce geographic disparities in time-to-treatment outcomes. 
5.1. Introduction 
In Canada, prostate cancer (PCa) is estimated to be the third leading cause of all cancer 
deaths (after lung and colorectal cancers) among men (1). Within Canada, Saskatchewan has the 
highest projected age-standardized PCa mortality rate (29.8 deaths per 100,000 in 2019) 
compared to all other provinces (1). Although it is not known what factors are leading to such 
high mortality rates in Saskatchewan, because delays to PCa treatments are known to adversely 
affect biochemical outcomes for high-risk PCa patients, in this study we explore waiting and 
delay factors possibly impacting PCa treatments in Saskatchewan (2-5). While there are four 
main types of PCa treatments (active surveillance/watchful waiting, surgery, radiation therapy 
(RT) and hormonal therapy), in this study we focus on RT (6). 
For RT, the Canadian Association of Radiation-Oncologists (CARO) has set a target 
wait-time of 14 days (7). However, the length of the wait-times varies by province (8). In 2013, 
Saskatchewan had reported wait-times of 27 days (for 90% of their PCa patients initiating RT), 
hence more work is needed to achieve the CARO wait-time target of 14 days (8). 
Looking at the PCa treatment centre availability in Saskatchewan, RT is centrally 
administered in two cities: Regina and Saskatoon (9). Consequently, nearly half of the 
Saskatchewan population (who live outside of these two cities) would commute to these two 
cities for treatment (10). Long commutes are a known barrier for patients living in the rural and 
remote areas of Saskatchewan (11, 12). In terms of RT for PCa, there are no known studies 
regarding the association between rural residence and wait-times in Saskatchewan. However, 
research from Australia shows cancer patients living in rural areas face longer delays for 
treatment compared to their urban counterparts (13, 14). Literature also shows patients living in 
rural regions have lower survival rates for cancers when compared to patients living in urban 
regions (15-19). Therefore, we hypothesize that patients living in remote regions of 
Saskatchewan face longer waiting periods for their PCa RT treatment. Two waiting periods of 
interest here are the ‘ready-to-treat’ to treatment period and the diagnosis-to-treatment period. 
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Our first objective is to determine the association (if any) between PCa patient ‘ready-to-
treat’ to treatment times for RT and the following factors: the remoteness level of where patients 
live; the closest PCa assessment centre for the patient; and other factors including patient’s age, 
risk levels, number of initial treatments and year of diagnosis. The second objective is to assess 
whether there is an association between the PCa patient diagnosis-to-treatment times for RT and 
the aforementioned factors.  
5.2. Methods 
5.2.1. Definitions 
Localized PCa is defined to be patients with low, intermediate and high risk levels based 
on the definitions of Genitourinary Radiation Oncologists of Canada (GUROC) (20). The initial 
treatment is defined as undergoing RT within 2 years of diagnosis (21). The Saskatchewan 
Cancer Agency defines the ‘ready-to-treat’ date as “the day on which the patient is ready to 
receive treatment, taking into account clinical factors and patient preference” (22). The ‘ready-
to-treat’-to-treatment time is defined to be the time between the “ready-to-treat” date and the 
initial treatment start date for RT (21). The diagnosis-to-treatment time is defined as the time 
between the diagnosis date and the initial treatment start date for RT (23). 
5.2.2. Data 
The Saskatchewan Cancer Registry (SCR) is a database for cancer patients diagnosed or 
treated in Saskatchewan. The study population were residents in the SCR from south central 
Saskatchewan who were diagnosed with localized PCa and received RT within Saskatchewan 
between 2010 and 2014. While the SCR contained information for 774 localized PCa patients 
undergoing RT (as initial treatment) within the study population, the study used data from 701 
patients (90.8%), after excluding patients living out-of-province at the time of diagnosis (36 
cases; 4.6%), those living in the three (17 cases; 2.2%) former northern health regions 
(Mamawetan Churchill River, Keewatin Yatthe, and Athabasca), and those patients with missing 
“ready-to-treat” date (20 cases; 2.3%). Those living in the northern health regions were excluded 
for privacy reasons because these health regions could not be subdivided into smaller 
geographical areas (GAs). The impact of excluding missing data was assessed using Little’s Test 
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for Missing Completely At Random (24, 25). The University of Saskatchewan BioMedical 
Research Ethics Board provided ethics approval (Bio-REB certificate #15-34).  
5.2.3. Outcome Variables 
5.2.3.1. ‘Ready-to-treat’-to-treatment (RTTx) time 
For the RTTx time, we computed the variable as: difference in the number of weeks 
between the date of “ready-to-treat” and date of RT treatment initiation (Figure 5.1) (21). In the 
literature, RTTx time is also termed as “wait-time” for RT and reported to be measured in days 
or weeks and we chose to use weeks as the unit of measure in this study (26, 27). Individuals 
with RTTx time values less than zero (that is, negative values) were deemed to be data entry 
errors and were excluded from the dataset (<10 cases). We considered fewer than five cases 
(with RTTx time greater than 30 weeks) to be extreme outliers because the RTTx time for all 
other cases ranged from 0 to 14 weeks. After removing these outliers, the final dataset consisted 
of 692 patients. 
 
 
Figure 5.1. ‘Read-to-treat’ to treatment (RTTx) time for radiation therapy (weekly). 
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Figure 5.2. Diagnosis-to-treatment time for radiation therapy (weekly). 
 
5.2.3.2. RT diagnosis-to-treatment time 
For the RT diagnosis-to-treatment time, we computed the variable as: difference in the 
number of weeks between the date of PCa diagnosis and date of RT treatment initiation (23). For 
consistency, the RT diagnosis-to-treatment time variable is also measured in weeks (Figure 5.2).  
5.2.4. Independent Variables 
The SCR subdivided central and southern Saskatchewan into 82 GAs using residence 
code boundaries for privacy reason (Figure 5.3 and Figure 5.4) (28). The cities of Saskatoon and 
Regina were two of these GAs (Figure 5.3 and Figure 5.4). Each of the 692 patients was 
categorized per the GA in which the patient lived at the time of diagnosis. 
To quantify how rural a GA was, we derived a remoteness score (a continuous variable) 
for each GA as the average of the Statistics Canada remoteness indices that were assigned to the 
residence code boundaries forming the GA (29). The GA remoteness index accounts for the 
following two factors: population size, and proximity to all population centres (29). The GA 
remoteness index ranged from 0.22 to 0.50 in the GAs in the study area. In general, major cities 
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in Saskatchewan and their surrounding areas have a GA remoteness index of less than 0.35. The 
GAs with no cities have a score of over 0.40 (in Saskatchewan, cities are defined to have a 
population of 5,000 or more) (30). The remoteness of each GA is illustrated in Figure 5.3.  
For each patient, we defined the “closest PCa assessment centre to a GA” in 
Saskatchewan as Regina or Saskatoon based on the minimum Euclidean distance between the 
centroids of the GA of the patient and the two cities (Figure 5.4). Those GAs that have 
Saskatoon as their closest PCa assessment centre are classified as the “Saskatoon area” and those 
GAs that have Regina as their closest PCa assessment centre are assigned as the “Regina area”. 
Because each patient had at least RT in the two years following diagnosis, we determined 
the number of PCa treatments for a patient to be: “1” if the patient only received RT; “2” if the 
patient received RT and one more treatment (surgery or hormonal therapy; grouped because of 
the small sample size if coded separately); and “3” if the patient received all three treatments 
(RT, surgery and hormonal therapy).  
The other variables included were age, year of diagnosis and risk levels as defined by 
GUROC (20).  
 
Figure 5.3. Remoteness index for each geographic area in Saskatchewan. 
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Figure 5.4. Closest PCa assessment centres of Saskatoon (green) and Regina (blue) for each 
of the geographic areas in Saskatchewan. 
 
5.2.5. Statistical Methods 
Based on the distribution of the RTTx time variable, non-parametric independent sample 
tests (Mann Whitney U two sample statistic and Kruskal-Wallis equality-of-population rank test) 
were conducted to assess any differences in the medians and distributions of the RTTx and 
diagnosis-to-treatment times by each variable of interest (31-34). 
In terms of multivariable analysis, Poisson regression analysis was considered due to the 
count nature of both outcome variables (35). Due to the variance of RTTx times being much 
larger than the mean of RTTx times, as well as lack of model fit (using goodness-of-fit test), a 
negative-binomial regression model was built (35, 36).  Next, due to the large number of zero-
values (37%) in the RTTx times, a zero-inflated negative model was also built (35). The best of 
these two models was assessed using the Akaike’s Information Criterion (AIC) (37). The zero-
inflated negative model was used due to the improved model fit (reduction of more than 2 units 
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in the AIC value) (37). For the RT diagnosis-to-treatment time, Poisson regression analysis was 
deemed the better model via the same process described for the RTTx time model. The 
diagnosis-to-treatment model additionally controlled for RTTx time because the length of RTTx 
time could affect the diagnosis-to-treatment time. 
The first step in the multivariate analysis was an unconditional analysis of each 
independent variable with the outcome. All the independent variables with p-value<0.20 (in the 
unconditional analysis) formed the initial multivariate model (38). Then backwards-manual 
model building was used and the best model was chosen based on the lowest AIC value; alpha 
was set at 0.05 (37). A confounding effect was assessed using a 10% change in the estimated 
effects of the other independent variables (39). Two-way interactions between the significant 
fixed-effect factors were identified based on a post-hoc Wald test and a reduction in AIC value 
(reduction of 2 units or more) (37, 40). 
Model diagnostics were conducted using deviance residuals, and we assessed the linearity 
of independent continuous variables to the linearized outcome by refitting the final models as a 
Box-Tidwell regression model (41, 42). Note that the final models were also built using “days” 
as the unit for RTTx times and diagnosis-to-treatment times, to determine the impact on the 
results. 
Descriptive statistics, non-parametric analysis, Poisson and negative binomial modeling, 
and Box-Tidwell regression (for diagnostics) were conducted in Stata/IC 15.1 for a Mac. The 
Euclidean distances were computed using quantum Geographical Analysis System (QGIS) 
Version 3.4.0-Madeira. Due to the availability of model diagnostics, the zero-inflated negative 
binomial models were built in R version 3.6.2 using the zeroinfl command within the “pscl” 
package (43). 
5.3. Results  
The RTTx time for 37% of the patients (258 patients) was 0 days. Half of the patients 
(median RTTx time) were treated within 1 week. Nine out of ten patients (90th percentile) were 
treated within 5 weeks. The interquartile range (IQR) of the RTTx time was 3 weeks and the 
range was 0 to 14 weeks.  
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For RT diagnosis-to-treatment time, the median was 23 weeks and the 90th percentile 
was 40 weeks. The IQR of the diagnosis-to-treatment time was 12.5 weeks and the range was 6 
weeks to 92 weeks. See Table 5.1 for detailed descriptive statistics. 
5.3.1. Non-parametric Analysis 
For the RTTx times, the Kruskal-Wallis tests show that the distributions for the following 
independent variables were different: GUROC risk levels and number of treatments (Table 5.2). 
To identify which categories within these independent variables had different medians, the Mann 
Whitney U tests were conducted. The median RTTx time for high-risk cases (1 week) was 
significantly lower than median RTTx time for intermediate-risk (2 weeks; P <0.0001) and low-
risk cases (2 weeks; p-value = 0.008).  
For the RT diagnosis-to-treatment times, the Kruskal-Wallis tests showed that the 
distributions for the following independent variables were different: GUROC risk levels, closest 
PCa assessment centre to a GA, and number of treatments (Table 5.2). Based on the Mann 
Whitney U tests, the median diagnosis-to-treatment time for high-risk cases (26 weeks) was 
significantly higher than median diagnosis-to-treatment time for intermediate-risk (19 weeks; P < 
0.0001) and low-risk (18 weeks; P < 0.0001). The median diagnosis-to-treatment time for 
patients in the Regina area (20.5 weeks) was significantly lower than median diagnosis-to-
treatment time for those patients in the Saskatoon area (25 weeks; P < 0.0001).  
5.3.2. Multivariable Analysis 
The multivariable models using days as the time unit had statistically consistent results 
with models using weeks as the time unit; hence for the sake of simplicity and comparing 
models, we only present the models using weeks.  
5.3.2.1. ‘Ready-to-treat’-to-treatment time 
In the RTTx time model, age and GA remoteness index were not included in the final 
model because they were not statistically significant and did not have a confounding effect. The 
final model consisted of year of diagnosis, number of treatments, risk levels and closest PCa 
assessment centre to a GA. In addition, we found a significant interaction effect between risk 
levels and the closest PCa assessment centre to a GA. 
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Table 5.1. Descriptive statistics for ‘ready-to-treat’ to treatment (RTTx) time and diagnosis-to-
treatment time outcomes (n=692). 
  RTTx time Diagnosis-to-treatment time 
 n Median 90th 
percentile 
Median 90th percentile 
Total 692 1 week 5 weeks 23 weeks 40 weeks 
Independent variables      
Age      
<60 97 1 week 5 weeks 23 weeks 42 weeks 
60 to 69 285 1 week 5 weeks 24 weeks 41 weeks 
70 to 79 279 1 week 6 weeks 23 weeks 38 weeks 
80 or above 31 1 week 6 weeks 21 weeks 37 weeks 
GUROC risk levels      
Low 35 2 weeks 7 weeks 18 weeks 35 weeks 
Intermediate 253 2 weeks 6 weeks 19 weeks 37 weeks 
High 404 1 week 4 weeks 26 weeks 43 weeks 
Year of diagnosis      
2010 136 1 week 5 weeks 26 weeks 47 weeks 
2011 135 1 week 7 weeks 23 weeks 38 weeks 
2012 163 1 week 6 weeks 23 weeks 35 weeks 
2013 120 1 week 4 weeks 22.5 weeks 42 weeks 
2014 138 1.5 weeks 6 weeks 21 weeks 37 weeks 
Closest PCa assessment 
centre to a GA 
     
Regina area 312 2 weeks 4 weeks 20.5 weeks 38 weeks 
Saskatoon area 380 1 week 6 weeks 25 weeks 41 weeks 
Number of treatments      
1 164 3 weeks 7 weeks 16 weeks 27 weeks 
2 479 1 week 4 weeks 25 weeks 39 weeks 
3 49 2 weeks 5 weeks 35 weeks 60 weeks 
Type of treatments*      
RT only 164 3 weeks 7 weeks 16 weeks 27 weeks 
RT and surgery 43 2 weeks 4 weeks 31 weeks 45 weeks 
RT and hormonal therapy 436 1 week 4 weeks 24 weeks 38 weeks 
RT, surgery and hormonal 
therapy 49 2 weeks 5 weeks 35 weeks 60 weeks 
Independent variable “GA remoteness index” not shown because it is not a factor variable. 
*Not an independent variable. Included as a descriptor for “Number of treatments”. 
 
In terms of year of diagnosis, between 2010 and 2014, those patients diagnosed in 2013 
had the shortest RTTx time. In terms of the number of treatments, the RTTx times for those 
patients with two treatments were 0.576 (95% CI: .452, 1.93; P < 0.001) times the RTTx times 
for those patients with one treatment. See Table 5.3 and Figure 5.5 for details. 
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Table 5.2. Non-parametric results - Kruskal-Wallis equality-of-populations rank test chi-square 
value and statistical significance.  
 RTTx time Diagnosis-to-treatment time 
 Chi-square P Chi-square P 
Age 0.543 0.9093 2.98 0.3942 
GUROC risk levels 15.5 0.0004 73.9 0.0001 
Year of diagnosis 3.38 0.4960 13.4 0.0095 
Closest PCa assessment centre to a GA 0.524 0.4691 27.3 0.0001 
Number of treatments 72.4 0.0001 168 0.0001 
Independent variable “GA remoteness index” not shown because it is not a factor variable. 
 
Table 5.3. Multivariable analysis results - incidence rate ratios (IRR) for fixed effect variables in the 
RTTx time and diagnosis-to-treatment models. 
RTTx time model RT diagnosis-to-treatment model 
 IRR (95% CI) P 
Year of 
diagnosis  < .001 
2010 Ref. cat.  
2011 1.22 (.954, 1.56) .112 
2012 .930 (.732, 1.18) .553 
2013 .682 (.519, .895) .006 
2014 1.02 (.796, 1.30) .889 
Number of 
treatments  < .001 
1 Ref. cat  
2 .576 (.452, .733) < .001 
3 .717 (.491, 1.05) .085 
 
 IRR (95% CI) P 
Year of 
diagnosis  < .001 
2010 Ref. cat.  
2011 .885 (.845, .927) < .001 
2012 .853 (.815, .892) < .001 
2013 .862 (.821, .905) < .001 
2014 .784 (.748, .822) < .001 
Number of 
treatments  < .001 
1 Ref. cat  
2 1.52 (1.45, 1.61) < .001 




1.45 (1.21, 1.75) < .001 




Table 5.4. Select pairwise contrasts for the interaction variables (GUROC risk levels and closest PCa 
assessment centre to a GA) for the RTTx time multivariable model. 
 RTTx time model 
 Contrast (95% CI) IRR (95% CI) P 
High risk patients in Saskatoon area vs  
High risk patients in Regina area .205 (-.012, .422) 1.23 (0.99, 1.52) .064 
Intermediate risk patients in Saskatoon area vs  
Intermediate risk patients Regina area .565 (.322, .809) 1.76 (1.38, 2.25) <.001 
Low risk patients in Saskatoon area vs  
Low risk patients in Regina .764 (.148, 1.38) 2.15 (1.16, 3.98) .015 
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Figure 5.6. Interaction between GUROC risk level and closest PCa assessment centre to a 
GA in the RTTx time model. 
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The RTTx time differences between the Saskatoon and Regina areas exist but only 
among intermediate and low-risk cases. Among all intermediate risk patients, those in the 
Saskatoon area had 1.76 (95% CI: 1.38, 2.25; P < 0.001) times longer RTTx time compared to 
patients in the Regina area. There was no difference in the RTTx times between the two areas 
among high-risk level patients (P =0 .064). See Table 5.4 and Figure 5.6 for details. 
5.3.2.2. RT diagnosis-to-treatment time 
In the RT diagnosis-to-treatment time model, age was not included in the final model 
because there was no statistical significance and confounding effect. The final model consisted 
of year of diagnosis, number of treatments, risk levels, GA remoteness index, closest PCa 
assessment centre to a GA and RTTx time. In addition, like the RTTx time model, we found a 
significant interaction effect between risk levels and the closest PCa assessment centre to a GA. 
In terms of the remoteness variable, RT diagnosis-to-treatment time is positively 
correlated with GA remoteness index (P < 0.001). Since the coefficient of GA remoteness index 
is 0.375, therefore an increase of 0.1 unit of GA remoteness index would be equal to an average 
increase in diagnosis-to-treatment time by 3.8% (Figure 5.7). 
The results of year of diagnosis and number of treatments are in Table 5.3 and visualized 
in Figure 5.8. Overall, there is a decrease in diagnosis-to-treatment time between 2011 and 2014 
compared to 2010. For the number of treatments, patients receiving one of either surgery or 
hormonal therapy with RT had 1.52 times longer diagnosis-to-treatment than those receiving RT 
only (P < 0.001). Patients receiving both surgery and hormonal therapy with RT had 2.23 times 
longer diagnosis-to-treatment for receiving RT only (P < 0.001). 
Those patients living in the Saskatoon area had 1.08 (95% CI: 1.01, 1.16; P = 0.035), 
1.15 (95% CI: 1.04, 1.28; P = 0.009) and 1.64 (95% CI: 1.24, 2.16; P < 0.001) times longer RT 
diagnosis-to-treatment time compared to patients living in the Regina area among high, 
intermediate and low risk patients, respectively (Table 5.5 and Figure 5.9). 
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Figure 5.7. Predicted diagnosis-to-treatment time by geographic area remoteness index. 
 
Table 5.5. Select pairwise contrasts for the interaction variables (GUROC risk levels and closest PCa 
assessment centre to a GA) for the radiation therapy diagnosis-to-treatment model. 
 Diagnosis-to-treatment  
 Contrast (95% CI) IRR (95% CI) P 
High risk patients in Saskatoon area vs  
High risk patients in Regina area .083 (.045, .120) 1.09 (1.05, 1.13) <.001 
Intermediate risk patients in Saskatoon area vs  
Intermediate risk patients Regina area .153 (.098, .207) 1.16 (1.10, 1.23) <.001 
Low risk patients in Saskatoon area vs  
low risk patients in Regina .498 (.356, .640) 1.65 (1.43, 1.90) <.001 
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Figure 5.8: Predicted diagnosis-to-treatment time by year of diagnosis and number of 
treatments. 
 
Figure 5.9. Interaction between risk level and closest PCa assessment centre to a GA for the 
diagnosis-to-treatment model. 
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5.4. Discussion 
This study shows that patients living in remote regions in Saskatchewan have longer 
diagnosis-to-treatment times for RT, but the RTTx times are not affected by GA remoteness 
index. Hence patients living in remote regions may face delays (or decide to delay their RT), but 
once they are in the cancer care system, those living in remote regions have similar RTTx times 
to those living in urban regions. This is an important finding, as it shows that those living in 
rural/remote areas are facing certain barriers to delay their RT in Saskatchewan, but once these 
patients are in the cancer care system, the RTTx times are not affected by where they live. In 
terms of treatment delays for PCa, to our knowledge, not many studies have assessed its 
association with remoteness, but studies for other cancer types show similar findings that living 
in rural areas affect time to treatment, including for colorectal and lung cancers (13, 14). Based 
on what is known from the international literature, healthcare access issues including travel time 
and distance, and availability of specialist appointments have been identified as barriers by 
physicians and patients regarding delays for treatments among rural patients (44, 45). Rural 
attitudes and cultures have also been identified as possible reasons why patients living in rural 
and remote areas may delay or face system delays for their treatments (45, 46). Further research 
is needed to identify if similar reasons are driving the delays in PCa treatment among patients 
living in remote areas in Saskatchewan. 
This study found that both RTTx and diagnosis-to-treatment times are longer in the areas 
with Saskatoon as the closest PCa assessment centre compared to Regina. A possible reason for 
the longer RTTx times in the Saskatoon areas is shown in the interaction effect with the risk 
level groups of the patients. There is difference in the RTTx times between the Saskatoon and 
Regina areas because those who are intermediate-risk and low-risk wait longer for their 
treatment in the Saskatoon area. Among high-risk group, there is no difference in the RTTx 
times between patients living in the two areas. While it is promising that the RTTx times for 
high-risk groups are similar in the two areas, it is not known why there are RTTx time 
differences between the two areas for low-risk and intermediate risk PCa patients. We know 
from a recent report that the median and 90th percentile for RTTx times in Saskatchewan were 
longest among low-risk groups (8), which is consistent with the findings of this study. A similar 
finding of longer diagnosis-to-treatment times among low-risk group PCa patients was found in a 
  91 
recent Canadian study (47). The total volume of RT in Saskatoon was higher than Regina in our 
data sample, which one may suspect as a potential reason for the difference in the RTTx times 
between the centres, but further research is needed.  Another possible reason could be due to 
difference in the interpretation of how RTTx is assigned in each of the centres, which requires 
further research. Future research involving interviews and surveys (mixed methods) of patients 
and frontline healthcare workers at the two centres could provide possible answers regarding the 
geographic disparities observed in this study. 
The average RTTx in both Saskatoon and Regina for all risk levels were less than three 
weeks (Figure 5.6). Based on communications with Saskatchewan Cancer Agency, RTTx of 
three weeks was the established target for 90% of the radiation therapy procedures during the 
study period in Saskatchewan (47). Although the average RTTx for PCa patients achieved this 
target (as per multivariable analysis), the 90th percentile (Table 5.1) for RTTx was 5 weeks (2 
weeks longer than the establish target), hence further measures might be needed to address the 
long waits between ‘ready-to-treat’ date and initial radiation therapy (47).  
Based on the multivariable analysis, this study found that patients receiving RT with 
surgery and/or hormonal therapy have longer diagnosis-to-treatment times. Based on Table 5.1, 
those who had RT and surgery had longer time to treatment compared to those who had RT and 
hormonal therapy. In addition, the longer diagnosis-to-treatment times among high-risk PCa in 
Table 5.1 could possibly be explained by a majority (393 out of 404; 97%) of the “high-risk” 
PCa patients received RT with surgery and/or hormonal therapy. The multivariable analysis 
accounted for other factors including the number of treatments, and it showed that high-risk PCa 
patients had the shorter diagnosis-to-treatment time compared to low risk patients (Figure 5.9). 
This study shows that RTTx and the diagnosis-to-treatment times were similar for 
patients of all age groups. This is consistent with a Canadian study that found no correlation 
between age and diagnosis-to-treatment time for RT among PCa patients (48). In terms of year of 
diagnosis, the RT diagnosis-to-treatment time appears to be decreasing over time between 2010 
and 2014. The reasons for these reductions is not known and requires further research. 
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5.5. Conclusions 
This study shows that patients living in remote regions in Saskatchewan have longer 
diagnosis-to-treatment times for RT, but the RTTx times are not affected by remoteness levels. 
In addition, both RTTx and diagnosis-to-treatment times are longer in the areas with Saskatoon 
as the closest PCa assessment centre to a GA compared to Regina. There is difference in the 
RTTx times between the Saskatoon and Regina areas (those who are intermediate-risk and low-
risk wait longer for their treatment in the Saskatoon area). Further research is needed to explore 
the personal reasons for rural and remote PCa patients for delaying their treatments. 
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CHAPTER 6 – FACTORS UNDERLYING TREATMENT DECISION-MAKING FOR 
LOCALIZED PROSTATE CANCER IN THE U.S. AND CANADA: A SCOPING REVIEW 
USING PRINCIPAL COMPONENT ANALYSIS 
Article reproduced with permission and minor edits. Originally published as: Andkhoie 
M, Meyer D, Szafron M. Factors underlying treatment decision-making for localized prostate 
cancer in the U.S. and Canada: A scoping review using principal component analysis. Can Urol 
Assoc J. 2018; 13(7): E220-E225; https://dx.doi.org/10.5489/cuaj.5538. My contributions to this 
study include study design, data analysis, interpretation of findings and manuscript preparation. 
In this chapter, we present the complete study used to address the research question 
“What factors and corresponding themes in the literature have been identified to affect the 
treatment decision-making of localized prostate cancer patients in Canada and the United 
States?” associated with our second study objective “to identify and describe the overarching 
themes influencing treatment decision-making for localized PCa patients”. Specifically, in this 
chapter we gather, collate, and identify key factors commonly studied in localized prostate 
cancer (LPC) treatment decision-making in Canada and the U.S. This scoping review uses five 
databases (Medline, EMBASE, CINAHL, AMED, and PsycInfo) to identify relevant articles 
using a list of inclusion and exclusion criteria applied by two reviewers. A list of topics 
describing the themes of the articles was extracted and key factors were identified using principal 
component analysis (PCA). A word cloud of titles and abstracts of the relevant articles was 
created to identify complementary results to the PCA. This review identified 77 relevant articles 
describing 32 topics related to LPC treatment decision-making. The PCA grouped these 32 
topics into five key factors commonly studied in LPC treatment decision-making: 1) treatment 
type; 2) socioeconomic/ demographic characteristics; 3) personal reasons for treatment choice; 4) 
psychology of treatment decision experience; and 5) level of involvement in the decision-making 
process. The word cloud identified common phrases that were complementary to the factors 
identified through the PCA. We identified several possible factors impacting LPC treatment 
decision-making. Further research needs to be completed to determine the impact that these 
factors have in the LPC treatment decision-making experience. 
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6.1. Introduction 
Prostate cancer is one of the most commonly diagnosed invasive cancers in Canada and 
the United States (US) (1-4). Localized prostate cancer (LPC), i.e., cancer contained within the 
prostate gland, accounts for about 79% of all prostate cancers diagnosed in North America (1). 
The progression of LPC to the metastatic stage has a substantial negative impact on the relative 
survival of the patients (the five-year relative survival decreases from 100% to 30%) (1). 
Therefore, the monitoring of the disease and undergoing necessary treatment(s) are important to 
prevent metastasis.  
The most common treatment types for LPC are active surveillance or watchful waiting 
(AS/WW), radiation therapy, surgery (prostatectomy), and hormonal therapy (5). Each treatment 
has different side effects (including incontinence and erectile dysfunction), impacting the 
quality-of-life for patients and their families (6-8). Therefore, it is necessary for physicians to 
make sure treatment choices align with patient needs and preferences. Studies on treatment 
decision-making focus on specific patient profiles, for example, ethnic and racial minorities, 
different age groups, and specific treatment types (9-16). While there is research describing 
treatment decision-making for varying LPC patient profiles, there is no literature 
comprehensively identifying common factors underlying treatment decision-making. 
The purpose of this research is to gather, collate and identify key factors commonly 
studied in LPC treatment decision-making in Canada and the United States. 
6.2. Methods 
Following the scoping review process of Arksey and O’Malley, we reviewed the 
literature to identify key factors for LPC treatment decision-making in Canada and the United 
States (17). The following steps were taken to compile the list of relevant articles: 
In step 1, one of the reviewers compiled the list of references from five databases 
(Medline, EMBASE, CINAHL, AMED and PsycInfo) using the search terms listed in Table 6.1.  
In step 2, the same reviewer from step 1 removed the duplicates in the list of references.  
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Table 6.1. Search terms used in the five databases. 
Terms describing prostate cancer Terms describing treatment decision-
making 
Prostatic neoplasms  Decision-making 
Prostate cancer Patient preference 
Prostatic AND neoplasms Patient participation 
(prostat* adj6 (cancer* or carcinom* or 
tumor* or tumour* or neoplasm* or 
adenocarcinom* or intraepithelial)) 
Decision support techniques 
Preferences 
Client participation 
Decision support systems 
Consumer participation 
Decision making support 
Choice behavior 
 
Table 6.2. Inclusion/exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
Peer-reviewed articles Commentaries, News, Abstracts 
English language Editorials, Case Studies, Reviews 
Specific to LPC Outside designated timeframe 
Exclusively regarding LPC Outside designated country of the 
corresponding author 
Specific to treatment decision-making Duplicate article 
Timeframe: September 1997 to August 2016  
Country of the corresponding author: the US 
or Canada 
 
Note: The geographical origin of the article was based on the country of the corresponding 
author (18). 
 
In step 3, the same reviewer from step 1 removed references outside the inclusion 
countries/timeframes and references that were not full-text peer-reviewed articles, and compiled 
a list of peer-reviewed articles.  
In step 4, two reviewers independently applied the inclusion/exclusion criteria listed in 
Table 6.2 to the titles and abstracts of the peer-reviewed articles and compiled a list of full-text 
review articles.  
In step 5, both reviewers independently conducted a full-text article review and applied 
the inclusion/exclusion criteria to the list compiled in step 4, and compiled a list of relevant 
articles.   
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The two reviewers discussed and resolved any disagreements to include/exclude articles 
in the fourth and fifth steps. The levels of agreement between the two reviewers in fourth and 
fifth steps were assessed using the Cohen Kappa Statistic. 
Two methodologies were then used to identify the key factors commonly studied in LPC 
treatment decision-making: 
First, both reviewers discussed and agreed upon the general topics identified within the 
relevant articles from step 5. A Principal Component Analysis (PCA) with Promax oblique 
rotation (loadings greater than 0.275 and less than -0.275 were grouped together) and a parallel 
analysis (with 1000 Monte Carlo simulation repetitions) were used to identify the underlying 
LPC treatment decision-making factors from these general topics (19-21). 
Second, a word cloud was created as a qualitative approach to identify complementary 
results to the PCA (first method) using word frequencies in the titles and abstracts of the relevant 
articles.  
All authors discussed and agreed upon the interpretations of the key factors identified. 
The Cohen Kappa statistic was calculated using IBM SPSS Statistics 22.0. PCA was conducted 
in Stata IC 12.1. Word Cloud was created in NVivo for Mac 11.4.1. 
6.3. Results 
In Step 1, the list of references from the five databases contained 1861 items.  Next, after 
duplicates were removed, 1200 articles remained. In Step 3, 559 articles were excluded (details 
in Figure 6.1) and a list of 641 peer-reviewed articles remained. In Step 4, out of the remaining 
641 articles, both reviewers agreed 89 articles needed full-text article review (Cohen’s Kappa 
Statistic 0.789; p<0.001). Upon full-text review of these articles, 77 articles were retained 
(Cohen’s Kappa Statistic 0.689; p<0.001). Among the retained articles, 55 (71%) were from the 
US and 22 (29%) from Canada. After the review, 32 general topics studied regarding LPC 
treatment decision-making were identified and are listed in Table 6.3.  
Applying PCA to the 32 identified topics resulted in five overarching factors (see Table 
6.3): treatment type, socioeconomic/demographic characteristics, personal reasons for treatment 
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choice, psychology of treatment decision experience, and level of involvement in the decision-
making process, based on the five highest eigenvalues that were generated from the PCA.  
Table 6.3: Key factors and their associated general topics extracted from the reviewed relevant 
articles. 
Key Factors General Topics Loadings 
Treatment types (9-16, 22-
65) 
Surgery (prostatectomy) 0.4643 
Radiation therapy 0.4093 
Active surveillance/watchful waiting 0.3717 
Brachytherapy 0.3636 
Hormonal therapy 0.2812 
Socioeconomic/demographic 
factors (10, 12, 14, 15, 23-
26, 28, 31, 32, 35-37, 41, 43, 
44, 46, 48, 53-55, 58, 59, 61-
63, 65-70) 
Sociodemographic factors 0.4482 
Monetary influences - cost, insurance 0.3944 
Race 0.3688 
Epidemiological studies on decision-making 0.3436 
Age 0.2766 
Personal reasons for 
treatment choice (9-16, 22, 
23, 25, 28-37, 40, 41, 43-47, 
50, 51, 55-63, 65-67, 70-84) 
Personal decision-making factors 0.4479 
Inconvenience and timing 0.3665 
Utilities and side effects 0.3267 
Fear of death/need for cure 0.3227 
Patient-use of decision aids -0.2893 
Actual or perceived health state/risk 0.2852 
Psychology of treatment 
decision experience (9, 12, 
13, 15, 16, 22-24, 26, 27, 29, 
30, 32, 33, 35, 36, 39, 41, 43, 
44, 46, 49, 51, 52, 55, 57, 59-
61, 63, 64, 66, 68-70, 72, 73, 
75-77, 79, 81, 83, 85) 
Confidence, regret and satisfaction 0.4664 
Stress/difficulty in decision-making 0.4338 
Psychology and coping factors 0.3488 
Marital Status 0.3344 
Post-treatment quality of life 0.3203 
Levels of involvement in 
decision-making (11-13, 15, 
16, 22-25, 27-31, 33-46, 48-
53, 55, 56, 59-68, 70-90) 
Physician role and influence 0.4894 
Shared/informed decision-making: active/passive 0.3808 
Behavior models using economic theories -0.3649 
Information and knowledge 0.3438 
Partner/family/friend participation and views 0.3038 
Note: Principal Component Analysis accounted for six other topics (“spirituality”, 
“multidisciplinary practice”, “consulting multiple providers”, “discordant decisions”, 
“complementary and alternative medicine”, and “health literacy”) partially within all five key 
factors.   
 
Associated with the highest eigenvalue (see Table 6.3 for values), the PCA grouped the 
LPC treatment type (including surgery and radiation therapy) as an overarching factor. 
Interestingly, LPC treatment type also emerged as the most frequently mentioned topic in the 
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word cloud. Therefore, both methodologies complement each other and show “treatment type” as 
a frequently studied LPC treatment decision-making factor in the literature. 
 
Figure 6.1. Methodology of identifying relevant studies for the scoping review and the 
results at each step. 
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Figure 6.2. Word cloud showing the most frequent words appearing in the titles and 
abstracts of the articles. 
 
 
Associated with the second highest eigenvalue, the PCA grouped age, income, race, 
insurance coverage and location where they live as another overarching factor. These 
socioeconomic/demographic characteristics pertain to patient-level information. From the word 
cloud (Figure 6.2), topics including “age”, “African American”, “Caucasian”, “education”, and 
“demographic” emerged, which are complimentary to the identified socioeconomic/demographic 
characteristics. 
Similarly, regarding the third highest eigenvalue, the PCA grouped six different reasons 
for treatment choice as a third overarching factor (see Table 6.3 for the list of topics under this 
factor). These reasons pertain to patient-level reasons for choosing or avoiding a treatment 
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option. Based on the word cloud, topics including “side effects”, “time”, “aid”, “months”, and 
“personal” emerged, which are complimentary to this identified key factor. 
With respect to the fourth highest eigenvalue, the PCA grouped factors pertaining to 
patients’ psychological experiences during the LPC treatment decision-making process (before 
and after the decision) as a fourth overarching factor.  The topics within this factor include 
uncertainty faced by patients before the treatment or regret/satisfaction of the decision after the 
treatment (see Table 6.3 for other topics within this factor). The list of words including “regret”, 
“satisfaction”, “conflict”, “quality-of-life”, “uncertainty”, “determined”, and “impact” in the 
word cloud are related to the psychology of treatment decision experience. 
Lastly, the PCA grouped the topics associated with the level of involvement for patients, 
their families, friends and the healthcare providers as a fifth overarching factor. There were 
several topics within the word cloud strongly suggestive of the topics associated with the roles in 
LPC treatment decision-making process, including “influence”, “physician”, “urologist”, 
“partners”, “considered”, “consultation”, “role”, “knowledge”, “control”, “support” and 
“involvement”. 
6.4. Discussion 
The PCA computed eigenvalues for each factor. These eigenvalues are a measure of the 
amount of variation in the information collected from the relevant articles regarding decision-
making themes: the higher the eigenvalue, the more frequently articles expressed topics 
associated with the factor.  The eigenvalues do not provide information on the level of 
importance of the factors.  For example, the factor “treatment type” (as discussed later) had the 
highest eigenvalue in the PCA, which does not imply it is the most important LPC treatment 
decision-making factor. In general, a factor having a higher eigenvalue does not imply it is more 
important than factors with lower eigenvalues.  
Based on these eigenvalues, our analysis identified five factors commonly studied 
regarding LPC treatment decision-making, including treatment type, patient 
socioeconomic/demographic characteristics, personal reasons of patients, psychological factors, 
and involvement level within the decision-making process. While the scoping review results 
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cannot be used to determine the importance of each of these factors, we hypothesize that they 
influence LPC treatment decision-making.  
Regarding how treatment type may be involved in LPC treatment decision-making, some 
research suggest patients prefer surgery or radiation therapy due to the perception level regarding 
side effects and perceived treatment invasiveness (12, 14-16, 50, 60, 62). Patients tend to prefer 
information on side effects or survival, which are different for each treatment type (38, 82, 90). 
Other work suggests patients might avoid invasive treatments or choose complementary 
alternative medicine (CAM) or AS/WW because: (i) they prefer to avoid the side effects of 
curative treatments; (ii) they are waiting for improvements in curative treatment options; and (iii) 
they perceive curative treatments to be inconvenient or a burden (9, 11, 13, 33, 34, 73). 
In terms of how socioeconomic/demographic characteristics contribute, some research 
studied the roles that age, race, income, education, type of insurance coverage and where one 
lives might have in LPC treatment decision-making (10, 14, 23, 26, 35, 53, 54, 58). For example, 
African-Americans with high risk LPC in the United States are less likely to receive treatment 
than Caucasians (91, 92). Other research suggests the availability of insurance can reduce these 
racial disparities (91, 92). Some patients not undergoing any treatment within six months of 
diagnosis were more likely to be older age (over 75), non-Caucasians and living in areas with 
fewer urologists (54). 
Personal reasons for a LPC treatment decision include survival probability, urinary 
function, rectal function, and ability to work (38, 82, 90). Some of the articles in this review 
contained decision aid tools available for educating patients about these personal reasons and 
assisting patients in making informed decisions (36, 57, 72, 74, 75, 79, 83, 84). 
Psychological experiences are a fourth factor that the PCA identified. These experiences 
include such things as feelings of stress, regret, uncertainty and questions regarding quality of 
life (27, 30, 35, 61, 66). There were reports of decisional regret among men with treatment side 
effects such as sexual, bowel or urinary dysfunction (27, 30, 35, 61, 66). Patients, who felt they 
were poorly informed or were not prepared enough regarding their treatments, were reported to 
have increased risk of regrets and psychological distress (13, 27, 32, 35, 36, 39, 46, 61, 66, 68, 
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69, 72, 81, 93). Men who were more actively involved in the decision-making and had greater 
knowledge of LPC were less likely to report decisional stress and had higher satisfaction.(64)  
The last factor identified by the PCA was level of patient involvement. Some LPC 
patients prefer an active or collaborative role with their physician in their treatment decision-
making (13, 15, 23, 24, 29, 71, 77, 84, 86, 87). When health care providers included patients in 
the treatment decision-making process, patients reported higher levels of satisfaction (88). 
Further, when patients discussed their treatment with physicians, families and friends, they 
reported an improved state of mind and ability to cope with their cancer diagnosis (49). 
Assessing the importance of each of the factors is needed because of their implications 
for improving patient decision-making experience and healthcare provider knowledge. Further 
studies are needed to identify the role, if any, that each of these factors have in LPC treatment 
decision-making. Further studies are also needed to see how the five factors interact with each 
other in shaping the LPC decision-making experience for patients. For those factors found to 
influence LPC treatment decision-making, interventions and policies could be developed to 
improve the decision-making experience for patients. 
6.5. Conclusions 
Our review identifies that there are five factors common to the LPC treatment decision-
making literature: treatment type, socioeconomic/demographic characteristics of the patients, 
personal reasons of patients, psychological factors, and level of involvement in the decision-
making process. Our study provides a basis for future research identifying the importance of 
each factor, and how they interact with each other in shaping the LPC treatment decision-making 
experience for patients. This future research has the potential to inform interventions and 
improve the LPC treatment decision-making experience for patient care. 
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CHAPTER 7 – CONCLUSIONS 
Overall, this work addressed two objectives. First, we determined associations between 
components of healthcare access and each of PCa incidence, treatment usage and time-to-
treatment trends among Saskatchewan patients. Second, we identified and described the 
overarching themes influencing treatment decision-making for localized PCa patients. 
 To address the first objective, in Chapters 3, 4 and 5, we explored the following research 
questions respectively: (1) “Is the PCa incidence in Saskatchewan affected by changes in family 
physician density, the remoteness level of where a patient lives, and the closest PCa assessment 
centre from where a patient lives?”; (2) “Are the PCa treatment utilization rates in Saskatchewan 
affected by changes in the remoteness level of where a patient lives and the closest PCa 
assessment centre from where a patient lives?”; and (3) “Are the PCa time-to-treatment 
outcomes in Saskatchewan affected by changes in the remoteness level of where a patient lives 
and the closest PCa assessment centre from where a patient lives?”. To address the second 
objective, in Chapter 6 we explored the following research question: “What factors and 
corresponding themes in the literature have been identified to affect the treatment decision-
making of localized prostate cancer patients in Canada and the United States?”.  
7.1. Summary of Findings 
In Chapter 3 we showed that disparities in PCa outcomes were associated with where 
patients live, including a higher than expected incidence of metastatic PCa in northern/central 
portions of Saskatchewan. In this chapter, we also showed a higher than expected incidence of 
intermediate-risk and low-risk PCa in the areas proximal to the city of Regina. In addition, we 
showed a negative association between physician density and standardized incidence ratio for 
metastatic PCa and high risk PCa. Hence higher physician density regions had lower than 
expected standardized incidence ratios for metastatic PCa and high risk PCa. The location where 
patients live and physician density could be viewed, respectively, as the accessibility and 
availability components of healthcare access factors as described by Penchansky and Thomas 
(1). Hence Chapter 3 illustrates the possible impact that healthcare access factors (location where 
patients live and physician density) may have on PCa outcomes, including geographic diagnosis 
patterns (standardized incidence ratios) in Saskatchewan.  
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In Chapter 4, we found that healthcare access factors including where patients live, 
remoteness level (urban and rural areas) and closest PCa assessment centre to a geographic area 
(GA) were associated with PCa treatment choices in Saskatchewan. Living in rural areas was 
negatively associated with choosing surgery compared to patients living near the major centres 
of Saskatoon and Regina. Those patients whose closest PCa assessment centre was Saskatoon 
had higher odds of undergoing radiation therapy treatment compared to Regina. In addition, 
those patients whose closest PCa assessment centre was Regina had higher odds of choosing 
active surveillance/watchful waiting compared to Saskatoon. Overall, healthcare access factors 
(where patients live, GA remoteness index and closest PCa assessment centre to a GA) were 
associated with PCa treatment choice (surgery, radiation therapy and active 
surveillance/watchful waiting) for patients in Saskatchewan. The location where patients live, 
GA remoteness index and closest PCa assessment centre to a GA possibly fall within the 
accessibility spectrum of healthcare access factors (1). Hence Chapter 4 showed the possible 
impact that healthcare access factors (GA remoteness index, location where patients live and 
closest PCa assessment centre to a GA) may have on PCa treatment choice in Saskatchewan.  
In Chapter 5, we showed that patients who live in remote regions in Saskatchewan had, 
on average, longer time-to-treatment outcomes for radiation therapy (specifically from date of 
diagnosis to start of radiation therapy treatment). In addition, this study found that time-to-
treatment outcomes were, on average, longer in areas with Saskatoon as the closest PCa 
assessment centre. Hence both healthcare access factors (GA remoteness index and closest PCa 
assessment centre to a GA) possibly impact PCa time-to-treatment outcomes in Saskatchewan.  
Chapter 6 identified five factors common to the localized PCa treatment decision-making 
literature: treatment type, socioeconomic/demographic characteristics of the patients, personal 
reasons of patients, psychological factors, and level of involvement in the decision-making 
process. Because these factors might influence localized PCA treatment decision-making, they 
could be further explored to improve PCa treatment making interventions and policies for 
patients. 
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7.2. Discussion and Policy Implications 
In this doctoral research, we showed geographic disparities exist in PCa incidence 
(Chapter 3), PCa treatment choice (Chapter 4) and PCa time-to-treatment outcomes (Chapter 5) 
in Saskatchewan. In addition, the work presented in Chapter 6 identified additional factors that 
might influence PCa decision making. Healthcare access factors, including location of patients, 
closest PCa assessment centre to a GA, GA remoteness index and physician density, were 
studied and identified to possibly impact PCa outcomes. 
The work in Chapter 3 shows the possible impact of healthcare provider availability on 
PCa outcomes, including the negative association between physician density and standardized 
incidence ratio for metastatic PCa and high risk PCa. In the literature, similar trends were found 
in the United States where availability of healthcare providers was negatively associated with 
incidence of late-stage diagnosis of PCa (2). Similar to the United States, we found in our study 
that PCa outcomes in Saskatchewan may be facing issues associated with availability of 
healthcare providers. Previous studies have shown the positive impact of increasing physician 
density on health outcomes (3-9). Hence, given the findings in Chapter 3, implementing policies 
addressing the adequate supply of healthcare providers, including availability of family 
physicians, might improve cancer outcomes in Saskatchewan.  
In Chapter 3, physician availability was negatively associated with the standardized 
incidence ratio for metastatic PCa and high risk PCa. This geographic trend in PCa incidence 
could possibly be due to physician practice differences in Saskatchewan, including differences in 
PCa screening practices among physicians (10). Historical PCa screening trends in Saskatchewan 
suggest incidence of PCa in Saskatchewan were possibly influenced by the usage of PCa 
screening tests (11, 12). In addition, it is known in the literature that decrease in PCa screening 
may possibly increase the incidence of advanced staged PCa (13). Therefore, physician practice 
variation including PCa screening usage might possibly explain the geographic trends in PCa 
diagnosis rates in Saskatchewan. Possible policy implications of addressing PCa screening may 
include government programs exploring other PCa screening methods, including urine-based 
tests and advanced prostate health index blood tests, as options provided to rural clients (14). The 
findings from Chapter 3 show the significance of addressing the pattern of late diagnosis of PCa 
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cases in north-eastern parts of Saskatchewan and addressing the possible associated healthcare 
access issues in the areas, including physician practice.  
The work in Chapter 4 shows the possible impact of healthcare provider accessibility on 
PCa treatment choice, including the negative association between living in rural/remote regions 
and choosing surgery for PCa treatment. The findings in Chapter 4 suggest that rural dwellers in 
Saskatchewan might be choosing PCa treatment differently than urban dwellers. In the literature, 
we found a similar trend in parts of United States and Australia where living in rural areas was 
associated with a lower likelihood to undergo PCa surgery (15-20). In the literature, possible 
reasons associated with treatment choice among rural dwellers were travel time, distance, 
availability of specialist appointments, and rural culture, including feeling like an outsider in city 
centres and less willingness to seek care in distant cities (21-23). These possible reasons, 
including travel to city hospitals may mean additional cost for the patients when seeking 
treatment, hence if similar reasons influence Saskatchewan patients living in rural areas, policy 
changes to address these disparities might include exploring reimbursement of travel and 
accommodation for PCa patients living in rural/remote areas in Saskatchewan (24). Therefore, 
based on the findings in Chapter 4, possibly offsetting the cost related to travel and financial loss 
might reduce the disparity in treatment trends among rural/remote patients in Saskatchewan (24).  
In Chapter 4, treatment utilization patterns were associated with changes in the 
remoteness level of patients and the closest PCa assessment centre to where patients live. We 
found usage of active surveillance/watchful waiting treatment was most common among older 
age and low-risk PCa patients. Based on the treatment guidelines, active surveillance/watchful 
waiting treatment would be recommended for patients with less than 10 years of life expectancy 
and those with low-risk PCa (25-27). Hence, Chapter 4 shows that the usage of active/watchful 
waiting treatment in Saskatchewan was consistent with the expected clinical treatment guidelines 
(25-27). For hormonal therapy, those with metastatic PCa were commonly receiving the 
treatment in Saskatchewan. The most common use of hormonal therapy among metastatic PCa 
patients aligns with the clinical treatment guidelines and shows Saskatchewan trends for 
hormonal therapy were consistent with what we may expect based on treatment guidelines (25-
27). The most common usage of radiation therapy and surgery among intermediate and high risk 
PCa patients was also consistent with the treatment guidelines (25-27). In addition, Chapter 4 
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shows radiation therapy was commonly used with hormonal therapy, which is expected based on 
the treatment guidelines (25-27). Overall, the treatment usage results by risk levels in Chapter 4 
were aligned with the expected clinical treatment guidelines (25-27). 
In Chapter 4, the treatment utilization patterns of patients living in the rural/remote areas 
and receiving radiation therapy treatment depended on the closest treatment centre for the 
patients (i.e., the interaction between remoteness index and closest PCa assessment centre). We 
found that patients had higher odds of receiving radiation therapy if their closest PCa assessment 
centre was Saskatoon compared to Regina (for both rural and urban areas). We also found that 
for those patients whose closest assessment centre was Regina, urban patients had a higher odds 
of receiving radiation therapy than rural patients. While we expected to see the same urban-rural 
disparity for radiation therapy treatment utilization in the Saskatoon area, we did not find this. 
Hence possible reasons for the differences between the Saskatoon and Regina areas need to be 
explored.  
Combining the work from Chapters 3 and 4, we found that the geographic location of 
patients (the accessibility component of healthcare access factors) was associated with PCa 
outcomes, including PCa SIRs (Chapter 3), and treatment choice (Chapter 4). Lower than 
expected incidence for low-risk PCa was found in the north-western part of Saskatchewan 
(Chapter 3), and the same surrounding areas had lower than expected utilization odds for active 
surveillance/watchful waiting (Chapter 4), which were complementary results because active 
surveillance/watchful waiting was more commonly utilized among low-risk PCa patients 
(Chapter 4). In terms of policy implications, geographic variation in low-risk PCa and utilization 
of active surveillance/watchful waiting could be indicative of a physician practice variation in 
diagnostic and treatment care within Saskatchewan; hence areas with lower than expected low-
risk PCa incidence and a lower odds of choosing active surveillance/watchful waiting may have 
differing PCa screening/diagnosis and active surveillance/watchful waiting practices, 
respectively, than other parts of Saskatchewan. Hence, the role of physician practice and 
availability of physicians might have impacted PCa outcomes in Saskatchewan. 
The work in Chapter 5 shows associations between healthcare provider accessibility on 
PCa time-to-treatment outcomes, including the positive association between living in 
rural/remote regions and time from diagnosis to radiation therapy treatment. In the literature, we 
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only found a similar trend for other types of cancers including lung and colorectal in studies from 
Australia (28, 29). Hence, the findings in Chapter 5 were unique to PCa treatment literature and 
it shows that rural dwellers in Saskatchewan might delay their PCa treatment due to where they 
live. Similar to Chapter 4, the possible reasons for these findings are travel time, distance, 
availability of specialist appointments, and rural culture including preference to stay closer to 
home for treatment and not preferring large city centres for seeking treatment  (21-23). The need 
for travel to seek treatment may have associated costs, including commuting costs and 
accommodations for the patients and possibly their families (24). Hence, since there may be a 
cost due to travel or possible loss of income due to travel time from rural areas, policies of 
reimbursing travel similar to Chapter 4 discussed in the previous paragraph could be explored as 
a means to possibly reduce the disparity in treatment delay trends among rural/remote patients in 
Saskatchewan (24).  
In Chapter 5, we found that the time-to-treatment from ‘ready-to-treat’ dates were longer 
for areas near Saskatoon when compared to areas near Regina, specifically among the low risk 
and intermediate risk patients (interaction effect between risk levels and closest PCa assessment 
centre). Among the high-risk patients, there were no differences between the areas near 
Saskatoon and Regina. A possible reason could be due to potential differences in the 
interpretation of how ‘ready-to-treat’ date is assigned in each of the centres and/or differences in 
the patient volumes in the two centres (Saskatoon and Regina).  Understanding if these are 
possible explanations requires further research. In addition, we found the time-to-treatment from 
‘ready-to-treat’ date periods to be shorter for clients having additional treatments, which requires 
further exploration and research at the treatment centres, including analysis of the patient flow at 
the treatment centres.  
In Chapter 5, the average wait for PCa radiation in Saskatoon and Regina were less than 
3 weeks. During the study period (2010 to 2014), the target wait period set was 3 weeks for 90% 
of the patients receiving radiation therapy including PCa patients (based on communication with 
Saskatchewan Cancer Agency). However, Chapter 5 shows that 90th percentile radiation therapy 
wait period was 5 weeks, which is 2 weeks longer than the target wait period. Based on the 
findings of Chapter 5, further measures may be needed to reduce the wait period between ‘ready-
to-treat’ date and initial radiation therapy for PCa patients, including addressing any physician 
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availability at Saskatoon and Regina treatment centres (based on communication with 
Saskatchewan Cancer Agency). Further research to assess the impact of increasing physician 
availability, staffing levels, and patient flow on time-to-treatment outcomes should be explored 
using dynamic simulation modelling to potentially identify system levels interventions, including 
standardization of patient flow at treatment centres in order to improve time-to-treatment 
outcomes. 
Combining the work from Chapters 4 and 5, we found that the closest PCa assessment 
centre to a GA (accessibility component of healthcare access factors) were found to be associated 
with choice of PCa treatment and treatment delays. For radiation therapy, those patients whose 
closest PCa assessment centre was Saskatoon had greater odds of choosing radiation therapy 
(Chapter 4) and had a longer waiting time for radiation therapy treatment compared to patients 
whose closest PCa assessment centre was Regina (Chapter 5). Areas with higher odds of 
choosing radiation therapy had lower odds of choosing active surveillance/watchful waiting 
(Chapter 4). These regional disparities between Saskatoon and Regina in treatment patterns 
could be due to differing physician practices as observed in other studies where physician advice 
could strongly influence the final treatment decision for PCa patients (30-32). The work in 
Chapters 4 and 5 showed regional disparities in treatment outcomes between Saskatoon and 
Regina, and the regional disparities may be due to differences in care practices between Regina 
and Saskatoon. Policies informing standardized care between Saskatoon and Regina in terms of 
wait time and treatment delays should be explored. 
The work in Chapter 6 identified possible additional factors that could affect PCa 
treatment decision, including treatment type, socioeconomic/demographic characteristics of the 
patients, personal reasons of patients, psychological factors, and level of involvement in the 
decision-making process. In terms of choosing or avoiding certain treatment types, patients could 
be influenced by their perceptions of treatment performance and side effects (33-39). Hence, 
policies involving decision aids to assist treatment decision-making could possibly reduce the 
uncertainties faced by patients (40-47). Socioeconomic/demographic disparities in choosing 
treatment were identified, including the role of income (33, 48-54). Financial hardship among 
cancer patients in Canada is known to be an issue and, if similar issues among PCa patients in 
Saskatchewan exist, policies to address the loss of income for cancer patients should be explored 
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(24). One possible gap in the Canadian literature was the reference to experiences on Indigenous 
peoples for PCa treatment decision making. Personal reasons for choosing a treatment included 
the avoidance of certain side effects of treatments including sexual function and the ability to 
make decisions in their preferred timeline (55, 56). Similar policy consideration of involving 
decision aids to assist treatment decision-making could possibly improve patient satisfaction 
with their treatment decision making journey (33-39). In terms of psychological factors, patients 
may face stress due to lack of information sharing by their healthcare provider (41, 42, 51, 57-
67). Hence, possible mechanism and policy to improve the patient decision making experience 
would need involvement of patients in the decision-making process (68). Research shows active 
participation of patients in treatment decision-making had a positive impact on their cancer 
management process (69). Hence, policies should be explored to improve the patient treatment 
decision making process, including decision aids, to address any patient financial barriers and 
facilitate shared decisions with the care providers. 
The findings from the international literature, including developed and developing 
countries, highlight the significance of expanding primary care availability in rural areas as a 
mechanism to reduce urban/rural disparities, due to the role of primary care in disease 
prevention, early detection of disease, and reducing mortality (70, 71). Expanding primary care 
in rural areas allows for better coordinating with other health services to improve the quality of 
life for patients (70, 71). Other common issues for rural areas include addressing barriers 
associated with travel and loss of income when seeking care, hence policies to reimburse travel 
and accommodation should be explored as possibilities to help address the rural disparities in 
PCa outcomes (24, 70, 71).  
The potential limitations of this doctoral research, include the PCa incidence patterns in 
Chapter 3 may have been influenced by the availability of urologists.  This limitation suggests 
the need for further research exploring the role of urologists in the PCa diagnosis patterns, 
including a sensitivity analysis to address the possible impact of urologist density on PCa 
incidence. In Chapter 4, due to gaps in the available data, those we identified as receiving active 
surveillance/watchful waiting may have included individuals whose PCa was unmanaged. To 
determine what proportion of patients had unmanaged PCa and what proportion were being 
actively surveilled, we suggest conducting chart reviews to address this limitation. In Chapter 4, 
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note our term “treatment choice” that we used to describe a treatment utilization pattern may not 
necessarily reflect an informed choice of a patient to choose a certain PCa treatment. In Chapter 
5, because of gaps in the available data, our term “delays” may include patient or system-based 
factors possibly impacting the longer time-to-treatment.  
7.3. Conclusions 
This doctoral research explored the possible reasons for the high mortality rates in 
Saskatchewan, when compared to other provinces. To explore the possible reasons for the 
adverse PCa survival outcomes in Saskatchewan, this work assessed two study objectives: (1) 
determining any associations between components of healthcare access and each of PCa 
incidence, treatment usage and time-to-treatment trends among Saskatchewan patients; and (2) 
identifying common factors influencing PCa treatment decision-making. Healthcare access 
factors, including location of patients, closest PCa assessment centre, remoteness and physician 
density, were studied and identified to possibly impact PCa outcomes. The work in Chapter 3 
showed the association between healthcare provider availability and PCa diagnosis patterns and, 
consequently, identified the possible need for an adequate supply of healthcare providers to 
improve cancer outcomes. The work in Chapters 4 and 5 showed the possible impact of 
healthcare accessibility on PCa treatment choice and delays, and therefore, identified the possible 
need for equitable policies to address urban/rural disparities in assisting patients with their 
treatment outcomes in Saskatchewan. The work in Chapter 6 informed future research to 
improve the treatment decision-making experience for PCa patients. Overall, this doctoral work 
identified the possible impact of healthcare factors on PCa outcomes, which may influence the 
adverse PCa outcomes in Saskatchewan, and the work identified factors that may further 
influence treatment decision-making. 
This doctoral research identifies the possible need for improving physician availability in 
Saskatchewan with an equitable geographic distribution of primary care providers to support 
early detection of PCa. Such policies may include improved access to specialty care based on the 
recommendations of Canadian Medical Association through streamlining patient flow, including 
standardized referral processes and physician practices (72). Other possible policies may include 
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expanding primary care, compensating patients for travel time, and additional investments in 
rural based treatment centres (24, 70, 71). 
7.4. Future Research Areas 
Based on the findings of Chapter 3, further research is needed to explore whether 
physician practice variation might be influencing the diagnosis patterns in Saskatchewan. 
Additional research to explore the role of urologist practice and availability may provide further 
insight in the PCa diagnosis patterns in Saskatchewan. In addition, further research is needed to 
identify the reasons for the clustering of higher incidence for early-stage PCa near the city of 
Regina and the clustering of late-stage PCa near the city of Saskatoon. Further research should 
be conducted to explore the role of healthcare access in northern Saskatchewan for PCa 
incidence, treatment utilization and time-to-treatment given the unique demographic with over 
85% of the population identifying as Indigenous (compared to 16% of the overall Saskatchewan 
population) and comprising of ‘fly-in’ communities. This research should include a sensitivity 
analysis using historical Saskatchewan Cancer Registry data to identify the possible impact of 
excluding northern Saskatchewan (due to the small cell size per outcome) from the analyses 
presented in this doctoral work.  
Computer simulation modelling that includes the latent progression of the PCa risk levels 
should be explored to account for disease progression and to improve estimates of undiagnosed 
late stage PCa cancer in Saskatchewan. Based on the findings of Chapter 4, further research is 
needed to explore whether rural access barriers including cost of travel, accommodation, 
financial factors and rural cultural components influence treatment decision patterns in 
Saskatchewan. In addition, further research is needed to identify the reasons for higher odds of 
radiation therapy in among patients whose closest PCa assessment centre is Saskatoon compared 
to Regina. It is not known why patients in rural areas have lower odds of undergoing surgery and 
further research is needed to identify the underlying reasons among rural dwellers in 
Saskatchewan. For active surveillance/watchful waiting, a possible chart review of client records 
should be explored to estimate the true prevalence of using active surveillance/watchful waiting 
among PCa patients in Saskatchewan. 
  127 
Based on the findings of Chapter 5, further research is needed to identify whether 
differences in care practice exist between Regina and Saskatoon and if it has any contributions to 
the longer waits in Saskatoon compared to Regina. This includes exploring reasons for shorter 
time to treatment from “ready-to-treat” date for clients using additional treatments. Based on the 
findings of Chapter 6, further research is needed to explore if the additional factors identified 
affect treatment decision-making among PCa patients in Saskatchewan. Further research is 
needed to identify the importance of each of the treatment decision-making factors in 
Saskatchewan. Lastly, research is needed as to whether the regional disparities in treatment 
outcomes (example, treatment delay) identified in Chapters 4 and 5 could be further impacted by 
the factors identified in Chapter 6. In addition, future research may also focus on exploring the 
changes in policies in the recent period between 2015 and 2021 in Saskatchewan compared to 
the baseline data from the study period (2010 to 2014) for each of the PCa outcomes, and assess 
the impact of recent cancer diagnosis and treatment policies on healthcare access in rural 
Saskatchewan. The findings of this doctoral work could be further translated to policy makers 
and stakeholders through presentations to the knowledge users, including Saskatchewan Medical 
Association, Saskatchewan Cancer Agency, Saskatchewan Health Authority, Saskatchewan 
Ministry of Health and organizations dedicated to improving health in rural and remote areas, 
including Indigenous organizations. Further research should be explored with other research 
centres related to chronic condition areas on healthcare access through presentations in the 
provincial, national and international conferences. The findings of this research would provide 
opportunities to explore whether healthcare access factors possibly impact other cancers, and 
chronic disease conditions in Saskatchewan.  
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